

9th INTERNATIONAL SYMPOSIUM **HODGKIN
LYMPHOMA**
COLOGNE, GERMANY

FINAL PROGRAM
October 12 – 15, 2013



accredited by



European Society for Medical Oncology



Ärztammer
Nordrhein (AEKNO)

www.hodgkinsymposium.org



Saturday (12.10.2013)		Sunday (13.10.2013)	Monday (14.10.2013)	Tuesday (15.10.2013)
08:30 – 13:45 Hematology Educational		07:30 – 08:30 GE Healthcare Symposium Novel Methodology to aid in the Diagnosis of Difficult HL Cases (V. Diehl)	07:30 – 08:30 Roche Symposium Beyond the revolution of MabThera (A. Engert)	07:30 – 09:00 Pediatric open session: Beyond the International Harmonization Criteria – New challenges in the application of imaging techniques for staging and response (J. Landmann-Parker, K. Kelly, A. Engert)
	Coffee	08:30 – 10:00 Interactive case discussions (R. Hoppe, P. Carde, J. Friedberg, P. Borchmann) • Case Presentations	08:30 – 10:00 Biology and microenvironment (M. Shipp, H. Stein) • Microenvironment in HL (R. Gascoyne) • Molecular pathogenesis of HL (M. Janz) • Deregulation of differentiation in pathogenesis of cHL (T. Wirth) • Oral Abstract Presentations	09:00 – 10:30 Survivorship (L. Specht, J. Friedberg) • Cardiac toxicity (J. Landman-Parker) • Breast cancer and other neoplasms (B. Aleman) • Fertility (K. Behringer) • Oral Abstract Presentations
	10:00 – 11:30 Workshops	Coffee Break	Coffee Break	Coffee Break
	• Prognostic and biomarkers – tissue and serum / plasma (C. Steidl, O. Casasnovas) • Closed workshop for pediatric groups (M. Metzger, J. Landman-Parker)	10:30 – 12:00 Pathways (A. v. d. Berg, M. Shipp) • JAK/STAT (M. Shipp) • Non-coding RNA and tumor cell survival (A. v. d. Berg) • CSF1 and CSF1R (St. Mathas) • Oral Abstract Presentations	10:30 – 12:00 Early stages (A. Polliack, R. Hoppe) • Update on the NCRI RAPID trial (J. Radford) • An update on the EORTC / LYSA / FIL H10 trial (J. Raemaekers) • WS report and further optimization in early stage HL (A. Engert) • Oral Abstract Presentations	11:00 – 12:30 Advanced stages (F. Morschhauser, R. Fisher) • Risk-adapted therapy in advanced stage HL: An update (M. Federico) • Can we improve ABVD? (St. Ansell) • Can we improve BEACOPP? (P. Borchmann) • Oral Abstract Presentations
	Coffee	12:15 – 13:45 Celgene Symposium Lenalidomide in Lymphoma – Latest Update on Clinical Data (A. Engert)	12:15 – 13:45 TEVA Symposium Non Hodgkin lymphoma – pathways to optimized treatment results (H. Ostermann)	12:45 – 14:15 MSD Symposium Update on Infectious Diseases in Hematology Patients (O. A. Cornely)
	12:00 – 13:30 Workshops			13:45 – 14:15 Poster Walk
	• GHSG workshop (GHSG participants only) (A. Engert, M. Fuchs) • Challenges in the development of new drugs in HL (A. Younes, P. Borchmann) • Radiotherapy of Hodgkin Lymphoma in 2013 (L. Specht, T. Illidge)	14:00 – 15:15 Amgen Symposium New Insights in the Treatment and Management of Lymphoid Malignancies (R. Pettengell)	14:00 – 15:30 HL in older patients (M. B. Agarwal, A. Lister) • Epidemiology and biology (M. Björkholm) • First line treatment (St. J. Proctor) • Relapsed HL in the elderly (B. Böll) • Oral Abstract Presentations	14:30 – 16:00 Relapsed (Ch. Gisselbrecht, A. Sureda) • What's new in relapsed HL? (B. v. Tresckow) • Debate: Is there still a role for allogeneic TX in HL? (Pro: K. Peggs Contra: A. Hagenbeek) • Oral Abstract Presentations
	14:00 – 15:30 Workshops	Coffee Break	Coffee Break	Coffee Break
	• New technologies for improving the therapeutic ratio of RT in HL (J. Yahalom, G. Mikhaeel) • PET (C. Moskowitz, M. Hutchings) • Somatic aberrations, epigenetic mechanisms and deregulated gene expression (W. Klapper, R. Gascoyne)	16:00 – 17:30 prIME Oncology Symposium, sponsored by Millennium / Takeda Relapsed/Refractory Hodgkin Lymphoma: Exploring Targeted Therapeutic Options (A. Engert)	15:45 – 17:30 PET and prediction (B. Coiffier, A. Gallamini) • PET for early response prediction (M. Hutchings) • PET review in GHSG trials (M. Dietlein) • PET in relapsed or refractory HL (C. Moskowitz) • Oral Abstract Presentations	16:15 – 18:00 Milestones in HL (F. Cavalli, J. Armitage) • Pathology (H. Stein) • Basic research (St. Mathas) • Prognostic indices and PET (B. Cheson) • Radiotherapy (R. Hoppe) • Clinical trials (V. Diehl) • New drugs (A. Younes)
	16:00 – 17:30 Workshops			18:00 – 18:30 Closing Remarks
	• Integrating PET into the management of early stage HL (J. Radford, A. Engert) • International Guidelines on follow-up and survivorship (J. Raemaekers, B. Cheson) • Genetic predisposition – HLA, GWAS, secondary malignancies, prognostic (A. Rosenwald, K. Hemminki)	18:00 – 20:00 Opening Ceremony	17:45 – 19:15 prIME Oncology Symposium, sponsored by Millennium / Takeda Defining Therapeutic Targets in T-Cell Lymphoma (B. Coiffier)	
	18:00 – 19:00			
	Johnson & Johnson Symposium Targeted Therapy: The Future in the Treatment of Malignant Lymphoma? (P. Borchmann)	Get Together		Speakers Dinner

Scientific Sessions / Main Program

Workshops

Educational

Satellite Symposia

Breaks



Final Program

October 12–15, 2013

Venue

Gürzenich Cologne
Martinstraße 29–37
50667 Cologne



German Hodgkin Study Group
Chair: Prof. Dr. Andreas Engert

Acknowledgements

The Local Organizing Committee wishes to express its appreciation and gratitude to the

We thank the following pharmaceutical companies which are generously supporting the meeting:


Platinum Sponsor



Gold Sponsors



Celgene GmbH
www.celgene.de



Teva Pharmaceuticals Industries, Ltd.
www.tevapharm.com



Karl Musshoff Stiftung.



Silver Sponsors



Amgen GmbH
www.amgen.de



GE Healthcare GmbH
www3.gehealthcare.com



Janssen Research & Development, LLC
www.janssenrnd.com



Merck & Co. Inc.
www.merck.com



Novartis Pharma GmbH
www.novartis.de



Roche Pharma AG
www.roche.de



Sanofi US
www.sanofi.us

Bronze Sponsors

Affimed Therapeutics AG
www.affimed.com

Chugai Pharma
www.chugaipharma.de

Cell Therapeutics, Inc
www.celltherapeutics.com

HEXAL AG
www.hexal.de

Janssen-Cilag GmbH
www.janssen-deutschland.de

Mundipharma GmbH
www.mundipharma.de

sigma-tau
www.sigma-tau.de

COME BY OUR BOOTH AT THE 2013 ISHL MEETING

Phase III trial in Hodgkin lymphoma



Phase III trial in cutaneous T-cell lymphoma



Phase III trial in frontline Mature T-Cell lymphoma



Learn more about studies for your
patients with **LYMPHOMAS**



Conference and Scientific Committee

Organizing Committee

Prof. Dr. Andreas Engert (Symposium Chairman)

Dr. Boris Böll (Congress Secretary)

Dr. Bastian von Tresckow (Congress Secretary)

German Hodgkin Study Group

Clinic I for Internal Medicine

University Hospital of Cologne

Kerpener Straße 62

D-50924 Cologne

Phone: +49 (0) 221.478-5933

Fax: +49 (0) 221.478-3778

E-Mail: info@hodgkinsymposium.org

Further Information: www.hodgkinsymposium.org

Conference Management & Industrial Exhibition Secretariat

Gabriele Hanke

Travel & Congress Activities

Marienburger Str. 8; D-40883 Ratingen

Phone: +49 (0) 2102.669 36

Fax: +49 (0) 2102.9648 29

E-Mail: info@tca-hanke.de

International Scientific Committee

M. B. Agarwal, J. Armitage, M. Björkholm, P. Carde, F. Cavalli,

B. Cheson, B. Coiffier, J. Connors, V. Diehl, M. Dietlein, M. Federico,

R. Fisher, J. Friedberg, A. Gallamini, R. Gascoyne, T. Girinsky,

C. Gisselbrecht, A. Hagenbeek, R. Hoppe, M. Hutchings,

P. Johnson, E. Kimby, R. Küppers, J. Landman-Parker, A. Lister,

S. Mathas, F. Morschhauser, C. Moskowitz, A. Polliack, J. Radford,

J. Raemaekers, A. Rosenwald, M. Shipp, L. Specht, H. Stein,

A. Sureda, A. van den Berg, J. Yahalom, A. Younes

Table of Contents

Exhibition	8
Welcome	11
General Information	12
Scientific Program	
Saturday, 12.10.2013	
Hematology Educational	18
Saturday, 12.10.2013	
Workshops Satellite Symposium	19
Sunday, 13.10.2013	
Scientific Program Satellite Symposium	24
Opening Ceremony	27
Monday, 25.10.2010	
Scientific Program Satellite Symposia	27
Tuesday, 15.10.2013	
Pediatric open session Scientific Program	31
Lunch Symposium	
Closing Remarks	34
Poster Presentations	
Advanced stages	35
Early stages	41
Biology and microenvironment	44
HL in older patients	49
Pathways	50
PET and prediction	55
Relapsed	59
Survivorship	65
Speakers and Chairs	72
FSA-Kodex	75
Awards	76
Imprint	80

- | | |
|-------------------------------|------------------------|
| 1 GE Healthcare | 2 Quintiles |
| 3 Sigma Tau Arzneimittel GmbH | 4 Janssen-Cilag GmbH |
| 5 Chugai Pharma | 6 Novartis Pharma GmbH |
| 7 TEVA | 8 Roche Pharma GmbH |
| 9 MSD Sharp & Dohme GmbH | 10 Celgene GmbH |
| 11 Amgen GmbH | 12 HEXAL AG |
| 13 Millennium/Takeda | |


Exhibition Hall

The Exhibition will take place in the Gürzenich in the "Isabellensaal" on the First Level.

Opening hours of the Exhibition

Sun. 13.10. 12:00-18:00 Mon. 14.10. 08:00-18:00

Tue. 15.10. 08:00-18:00




Welcome

Dear colleagues and friends,

We warmly welcome you to our 9th International Symposium on Hodgkin Lymphoma (ISHL-9). This symposium has become the central forum for clinicians and scientists for a comprehensive exchange of up-to-date results and new ideas. Discussing the relevance of new findings for daily clinical practice in Hodgkin Lymphoma is one of the major goals of this symposium, which is hosted by the German Hodgkin Study Group (GHSg). It will be held again at the Gürzenich in Cologne, which is a wonderful communicative environment for scientific discussion and networking.

ISHL-9 will cover the most recent results in basic research, diagnosis and treatment of Hodgkin Lymphoma and related malignancies. Satellite symposia and scientific workshops will complement the program. In addition, there will be interactive case discussions and a Hematology Educational. This year, there is a special emphasis on risk adapted therapy and new drugs. The Karl-Musshoff-Price for outstanding life time achievements in the field of Hodgkin Lymphoma and the Hodgkin Lymphoma Award will be presented during the opening ceremony. Additionally, five best abstract awards and five young investigator awards have been designated based on the abstract evaluations of an international committee.

We thank all our encouraged contributors and cordially welcome you to the
9th International Symposium on Hodgkin Lymphoma (ISHL-9)!



Andreas Engert
Congress Chairman



Boris Böll
Congress Secretary



Bastian von Tresckow
Congress Secretary

General Information

Conference Secretariat

Gürzenich Cologne
Martinstraße 29-37
50677 Cologne

During the Conference the Secretariat can be reached at

Phone: +49 (0) 173.939 07 30
E-Mail: info@tca-hanke.de

Opening Hours of the Conference Secretariat

Saturday, October 12 th , 2013	08:00 – 18:00	(Dorint Hotel)
Sunday, October 13 th , 2013	07:00 – 18:00	(Gürzenich)
Monday, October 14 th , 2013	07:00 – 18:00	(Gürzenich)
Tuesday, October 15 th , 2013	07:00 – 18:00	(Gürzenich)

Accommodation

If you are still in need of a hotel room, please contact the conference management:
Phone: +49 (0) 2102.669 36
E-Mail: info@tca-hanke.de

Badge

Participants are requested to wear their badge at all times during the conference including satellite symposia. A replacement fee will be charged for lost badges.

Catering

Complimentary coffee will be served during breaks at the conference. Lunch will be available for participants of satellite symposia on Sunday, Monday and Tuesday.

Cloakroom

A cloakroom is available in the basement.

Conference Language

The conference language is English.
There will be no translation into other languages.

Continuing Medical Education

The 9th International Symposium on Hodgkin Lymphoma will be certified by AEKNO with a total of 21 points for the entire meeting. The meeting will be also certified by the ESMO granting 21 ESMO-MORA category 1 points, as well as the EHA, granting 23 EHA-CME points.

The Hematology Educational has been accredited with 5 category 1 ESMO-MORA points.

Please collect your certificates before departure at the registration desk (entrance hall of the Gürzenich).

Insurance

The meeting organizers cannot accept liability of personal injuries sustained or for loss or damage of property belonging to congress participants, either during or as a result of the meeting.

Internet (by courtesy of Millennium /Takeda)

All participants will have free access to High Speed Wireless Internet at the Gürzenich Conference Center at no extra cost. This service is being made available by Millennium /Takeda. Further details such as access codes will be provided on site. Two internet terminals will be provided allowing internet browsing and access to web based mail.

Registration

Pre-registration will close on October 5th. All registrations received on or after October 6th will be considered on site registrations and will be charged on site fee.

Full registration will include access to the scientific sessions and exhibition, a copy of the program and abstract book, welcome reception on Sunday October 13th and all refreshment breaks. Name tags will be issued and will be required at all conference events including satellite symposia. No refund will be possible.



Speakers Ready Room

On Saturday, October 12th, the Speakers Ready Room is located on the ground level of the Dorint Hotel (*Landskrone room*).

On all the following conference days, the Speakers Ready Room is located on the ground level of the Gürzenich Conference Center next to the registration desk. Speakers are requested to bring their PowerPoint presentations at least 3 hours before their session starts or the day before if the session starts early in the morning. Only Windows PowerPoint files can be accepted. No laptop presentations will be allowed in the session rooms.

Non-Smoking

There will be a strict non-smoking policy within all areas of the facilities used by the conference.

Transportation

The airports closest to Cologne City are Cologne / Bonn Airport (15 km) and Düsseldorf Airport (45 km).

From Cologne / Bonn Airport you can reach Cologne central station by rapid transit railway and regional express network (both 30 minutes), the trip from Frankfurt Airport to Cologne by Inter-City Express (ICE) takes just an hour.

Cologne central station is within walking distance (10 minutes) from the Gürzenich Conference Center and the Dorint Hotel. You may also take bus no. 132 to the stop "Gürzenichstraße". The other hotels recommended by the Congress Organization can easily be reached by public transport. Cologne has an efficient public transport system. Yet the recommended hotels, the venue as well as other places of interest are within a comfortable walking distance from each other. For those who are traveling by car we recommend the parking ground "Heumarkt" – about 3 minutes walking distance from the Gürzenich.



Additional information for Sunday, October 13th

On Sunday, October 13th, 2013 the "Cologne Marathon" will take place. From about 07:00 am until approximately 06:00 pm, there will be a number of actives and spectators over the 42 kilometers distance within the city of Cologne.

Some participants arriving Sunday morning (October 13) might be confronted with a complex traffic situation if they arrive by car and might face deviations when reaching the last kilometers to their final destination. Whereas the official parking facilities can be reached mostly all the time, some of the hotel parking areas might be closed.

Additional information including maps of the city and the marathon route with corresponding hints will be provided online at www.hodgkinsymposium.org in due time. We strongly recommend making yourself well acquainted with the individual locations you are considering beforehand. Please calculate some more time as the open roads to the conference center Gürzenich, the parking facilities and some of the hotels will be crowded and in some cases might even be closed temporarily.

All other visitors of our conference arriving by Saturday, October 12th or on Sunday October 13th after 06:00 pm will reach their final destination without further delay or restrictions. Thank you for your kind attention and preparation in order to manage your arrival as smooth as possible.



Welcome Reception

On Sunday evening the conference will be opened officially. After the Opening Ceremony we invite all participants to our Get Together in the Gürzenich Conference Center. This event will also enable members of the scientific and medical community to get to know their colleagues over a drink and snack.

Leisure and Cultural Activities

The *Gürzenich Conference Center* is situated right in the heart of Cologne, an ideal location to explore all the different facets of one of the liveliest towns in Germany.

The Conference Site: Since its completion in 1447, the Gürzenich was the largest secular building of the city from the middle ages, with its Gothic façade and its turret-framed roof. It was used to receive the most important guests including Kings and Queens. Major reconstruction followed in the 19th century.

The Köln-Marathon: As mentioned above, the yearly "Rhein Energie Marathon Köln" will take place during the conference on Sunday, October 13th. The runners will pass just around the corner from the conference site about 1 km before crossing the finish line at the cathedral. Although this might cause some deviations for ISHL-participants arriving at the conference, don't miss the chance for a glimpse at the runners including Kenyan and Ethiopian world-class athletes and an impression of the world-famous vibrant and supporting atmosphere provided by the crowds.



Walking around the Old Town: Located between the lovely Rhine embankment promenade and the cathedral the old town offers fresh air and nice walks. To get a bird-eye-view of the town you might wish to climb the cathedral tower. The *Farina House* just across the Gürzenich is the birthplace of *Eau de Cologne*. It portrays a particular section of Cologne's economic and social history via the perfume industry. Walking a bit further along the Rhine you will see a shiny glass building extending into the river. It houses the unique *Chocolate Museum* – a very nice place to relax.

Culture: Both, an architectural and a cultural highlight is the *Kolumba*, the art museum of the archbishopric of Cologne. The fascinating new building was designed by *Peter Zumthor* and houses an impressive collection of art from late antiquity to the present. A place you also shouldn't miss is the *Museum Ludwig* where you can find one of the most distinguished collections of 20th century art ranging from Russian avant-garde to works of famous contemporary artists.

Beer Culture: The place to delve into the town's beer culture is *Brauhaus Früh*. If you prefer a smaller cosier place you could try *Altstadt Pöffen* – both places offer hefty meals well suited before a round of beer.

Shopping: The main shopping streets are *Schildergasse* and *Hohe Straße*. If you are looking for a smaller exclusive choice we recommend the *Mittelstraße*. In Germany shops do not open Sundays however the shopping arcade at the train station is open 7 days a week.

Hematology Educational

08:30 – 13:45 | Dorint-Hotel **Room: Pipin II**

A faculty of renowned international experts will present standard of care and recent advances in the management of other lymphoma and chronic leukemias.

Topic	Speaker
Chronic Lymphocytic Leukemia (CLL)	M. Hallek
Mantle Cell Lymphoma (MCL)	M. Dreyling
Follicular Lymphoma (FL)	E. Kimby
Aggressive Non-Hodgkin-Lymphoma (NHL)	M. Pfreundschuh
Multiple Myeloma (MM)	M. Dimopoulos
Chronic Myeloid Leukemia (CML)	P. La Rosée

Accredited with
5 ESMO-MORA cat. 1 points



European Society for Medical Oncology

Workshops Dorint Hotel

Workshop 1 (parallel sessions)

10:00 – 11:30

Prognostic and biomarkers – tissue and serum / plasma **Room: Pipin I**

Christian Steidl (Vancouver, CDN), Olivier Casasnovas (Dijon, F)

The immunomodulatory and angiogenic protein Galectin 1 is a circulating biomarker in Hodgkin Lymphoma
Margaret Shipp (Boston, USA)

Plasma TARC as a treatment response marker and prognostic tissue biomarkers in classical Hodgkin Lymphoma
Arjan Diepstra (Groningen, NL)

Prognostic biomarkers from gene expression profiling in formalin-fixed paraffin-embedded biopsies
Christian Steidl (Vancouver, CDN)

Flow cytometry studies of lymphocyte predominant cells from nodular Lymphocyte Predominant Hodgkin Lymphoma
Jonathan Fromm (Seattle, USA)

Identification of CD8 'follicular cytotoxic' cells in tumor infiltrating T cells from classical Hodgkin lymphoma
Luc Xerri (Marseilles, F)

Workshop 2 (parallel sessions)

10:00 – 11:30

Closed workshop for pediatric groups **Room: Sandkaul**

Monika Metzger (Memphis, USA), Judith Landman-Parker (Paris, F)

Overview of international harmonization of staging and response criteria in pediatric Hodgkin Lymphoma – summary of results thus far
Monika Metzger (Memphis, USA)

Highlights and controversies found between existing major pediatric groups
David Hodgson (Toronto, CDN)

Discussion
Judith Landman-Parker (Paris, F)

Workshop 3 (parallel sessions) 12:00 – 13:30

GHSg workshop Room: Martin & Augustin

Andreas Engert (Cologne, D), Michael Fuchs (Cologne, D)

GHSg participants only. Workshop language German

Workshop 4 (parallel sessions) 12:00 – 13:30

Radiotherapy of Hodgkin Lymphoma in 2013

Room: Pipin I

Lena Specht (Copenhagen, DK), Tim Illidge (Manchester, UK)

New concepts of field and dose: Implications for disease control and long-term outcome Lena Specht (Copenhagen, DK)

The role of radiotherapy in early stage and the relevance of PET response Tim Illidge (Manchester, UK)

Is radiotherapy still relevant for patients with advanced stage disease and in salvage of chemotherapy failures? Joachim Yahalom (New York, USA)

Workshop 5 (parallel sessions) 12:00 – 13:30

Challenges in the development of new drugs in Hodgkin lymphoma Room: Severin

Anas Younes (New York, USA), Peter Borchmann (Cologne, D)

Progress on new drug development in Hodgkin lymphoma Alison Moskowitz (New York, USA)

Clinical trials design, response assessment, and trial end points Anas Younes (New York, USA)

Challenges of translation of abundant new data into clinical trials in rare diseases Peter Borchmann (Cologne, D)

Challenges of preclinical models Bastian von Tresckow (Cologne, D)

Workshop 6 (parallel sessions) 14:00 – 15:30

New technologies for improving the therapeutic ratio of RT in Hodgkin lymphoma Room: Pipin II

Joachim Yahalom (New York, USA), George Mikhaeel (London, UK)

Optimizing and using imaging for RT planning George Mikhaeel (London, UK)

Advanced conformal RT for reduction of normal organ exposure Umberto Ricardi (Turin, I)

Techniques for reduction of breast exposure Bouthaina Dabaja (Houston, USA)

Breath-hold techniques Peter Meidahl Petersen (Copenhagen, DK)

Proton therapy for Hodgkin Lymphoma Bradford Hoppe (Jacksonville, USA)

Early detection of breast cancer Andrea Ng (Boston, USA)

Workshop 7 (parallel sessions) 14:00 – 15:30

PET Room: Pipin I

Craig Moskowitz (New York, USA), Martin Hutchings (Copenhagen, DK)

The new NCCN guidelines and the role of PET / CT Craig Moskowitz (New York, USA)

Imaging and PET / CT recommendations for the revised staging and response criteria Martin Hutchings (Copenhagen, DK)

Metabolic tumor volume and other new concepts Lawrence H. Schwartz (New York, USA)

qPET – a quantitative approach to assess response in interim FDG-PET scans in lymphoma Dirk Hasenclever (Leipzig, D)

Workshop 8 (parallel sessions)**14:00 – 15:30****Somatic aberrations, epigenetic mechanisms and deregulated gene expression** **Room: Severin**

Wolfram Klapper (Kiel, D), Randy Gascoyne (Vancouver, CDN)

Novel and recurrent coding sequence mutations in microdissected Hodgkin-/Reed-Sternberg cells

Christian Steidl (Vancouver, CDN)

No chance for a comeback? The multiple ways to block the B-cell phenotype in Hodgkin Lymphoma

Michael Hummel (Berlin, D)

New insights into the transcription factor network of Hodgkin-/Reed-Sternberg cells

Stefan Mathas (Berlin, D)

Transcriptome analysis of Hodgkin and Reed-Sternberg cells enriched from Hodgkin Lymphoma biopsies: an approach to virus discovery

Ruth Jarrett (Glasgow, UK)

Downregulation of FOXO1 prevents induction of the tumor suppressor PRDM1 in cHL

Marion Vogel (Ulm, D)

Workshop 9 (parallel sessions)**16:00 – 17:30****Integrating PET into the management of early stage Hodgkin Lymphoma** **Room: Pipin I**

John Radford (Manchester, UK), Andreas Engert (Cologne, D)

Introduction

Andreas Engert (Cologne, D)

RAPID trial: Update and lessons in standardized interpretation of PET

John Radford (Manchester, UK)

BCCA experience: Population-based PET guided treatment

Richard Klasa (Vancouver, CDN)

Challenges applying PET for early stage disease

Martin Hutchings (Copenhagen, DK)

What did EORTC H10 teach us?

Massimo Federico (Modena, I)

Formulation of conclusions and identification of important outstanding questions

John Radford (Manchester, UK)
Andreas Engert (Cologne, D)

Workshop 10 (parallel sessions)**16:00 – 17:30****International guidelines on follow-up and survivorship** **Room: Martin & Augustin**

John Raemaekers (Nijmegen, NL), Bruce Cheson (Washington, USA)

Some "philosophical" introductory remarks on the need and pitfalls of long-term follow-up

Alexander Fossa (Oslo, N)

The ASCO and the Dutch guidelines

Louis S. Constine (Rochester, USA)
Nicky Dekker (Amsterdam, NL)

Minimizing treatment and its consequences for long term toxicity and follow-up

John Radford (Manchester, UK)

Reducing RT to involved node principle and its consequences for long-term toxicity and follow-up

David Hodgson (Toronto, CDN)

General discussion

Workshop 11 (parallel sessions)**16:00 – 17:30****Genetic predisposition – HLA, GWAS, secondary malignancies, prognostic** **Room: Severin**

Andreas Rosenwald (Würzburg, D), Kari Hemminki (Heidelberg, D)

Familial risks and germline genetics of Hodgkin Lymphoma

Kari Hemminki (Heidelberg, D)

HLA locus and risk of Hodgkin Lymphoma

Hauke Thomsen (Heidelberg, D)

Multiple neoplasias after Hodgkin Lymphoma; incidence and risk factors

Berthe Aleman (Amsterdam, NL)

Genetic defects of T-cell function predisposing for EBV-associated lymphoproliferation and Hodgkin Lymphoma

Kirsten Bienemann (Düsseldorf, D)

General discussion

Satellite Symposium 18:00 – 19:00 (Janssen Pharmaceutical Research & Development)

Targeted Therapy: The Future in the Treatment of Malignant Lymphoma **Dorint Hotel, Pipin I & II**

Peter Borchmann (Cologne, D)

New approaches in the treatment of mantle cell and other Non Hodgkin Lymphoma Anas Younes (New York, USA)

New horizons in the treatment off CLL Michael Hallek (Cologne, D)

Sunday, 13.10.2013

Satellite Symposium 07:30 – 08:30 (GE Healthcare)

Novel Methodology to aid in the Diagnosis of Difficult Hodgkin Lymphoma Cases **Gürzenich, Großer Saal**

Volker Diehl (Cologne, D)

07:30 – 07:40
Introduction and Perspective Volker Diehl (Cologne, D)

07:40 – 08:05
Novel methodology to aid in the diagnosis of difficult lymphoma cases Lawrence Weiss (Duarte, USA)

08:05 – 08:20
Case Series Presentation using MultiOmyx Methodology Lawrence Weiss (Duarte, USA)

08:20 – 08:30
Questions & Answers

Scientific Session 1 08:30 – 10:00

Interactive case discussions **Gürzenich, Großer Saal**

Richard Hoppe (Stanford, USA), Patrice Carde (Villejuif, F), Jonathan Friedberg (Rochester, USA), Peter Borchmann (Cologne, D)

Presentation of difficult and controversial Hodgkin Lymphoma cases with a focus on interaction and discussion

Scientific Session 2 10:30 – 12:00

Pathways **Gürzenich, Großer Saal**

Anke van den Berg (Groningen, NL), Margaret Shipp (Boston, USA)

10:30 – 10:50
JAK / STAT Margaret Shipp (Boston, USA)

10:50 – 11:10
Non-coding RNA and tumor cell survival Anke van den Berg (Groningen, NL)

11:10 – 11:30
CSF1 and CSF1R Stefan Mathas (Berlin, D)

11:30 – 11:40 | T083
Integrated genomic analysis of flow sorted Hodgkin and Reed-Sternberg cell in primary classical Hodgkin lymphoma
Jonathan Reichel (New York, USA)

11:40 – 11:50 | T084
TCF3 / E2A (19p13.3) is a novel Hodgkin Lymphoma susceptibility locus; a meta-GWAS study from the Interlymph Hodgkin Lymphoma consortium
Anke van den Berg (Groningen, NL)

11:50 – 12:00 | T085
Hodgkin-Reed-Sternberg cells in classical Hodgkin lymphoma show alterations of genes encoding the NADPH oxidase complex and impaired reactive oxygen species synthesis capacity
Maciej Giefing (Kiel, D)

Lunch Symposium 12:15 – 13:45 (Celgene GmbH)

Lenalidomide in Lymphoma – Latest Update on Clinical Data **Gürzenich, Großer Saal**

Andreas Engert (Cologne, D)

12:30 – 12:55
Rationale and Clinical Experience with Lenalidomide in Hodgkin Lymphoma Boris Böll (Cologne, D)

12:55 – 13:20
Progress in the treatment of Aggressive B-Cell Lymphomas Grzegorz S. Nowakowski (Rochester, USA)

13:20 – 13:45
Emerging treatment options for mantle cell lymphoma Pier Luigi Zinzani (Bologna, I)

Satellite Symposium (Amgen GmbH)

14:00 – 15:15

New Insights in the Treatment and Management of Lymphoid Malignancies

Gürzenich, Großer Saal

Ruth Pettengell (London, UK)

14:00 – 14:25

New Aspects on Dose Density in Malignant
Lymphoma

Ruth Pettengell (London, UK)

14:25 – 14:50

The impact of hematological toxicity
in Hodgkin LymphomaPeter Borchmann
(Cologne, D)

14:50 – 15:15

Bispecific CD19 antibodies – a new
treatment principle for management of
relapsed / refractory ALL and NHLNicola Gökbuget
(Frankfurt, D)

Satellite Symposium (prIME Oncology, supported by Millennium / Takeda)

16:00 – 17:30

Relapsed/Refractory Hodgkin Lymphoma: Exploring Targeted Therapeutic Options

Andreas Engert (Cologne, D) Gürzenich, Großer Saal

16:00 – 16:05

Welcome and Introduction

Andreas Engert (Cologne, D)

16:05 – 16:20

The challenge of relapsed Hodgkin Lymphoma
in the era of contemporary therapy

Andreas Engert (Cologne, D)

16:20 – 16:25 Q&A

16:25 – 16:40

Defining the ideal target in Hodgkin Lymphoma

Stefano Pileri (Bologna, I)

16:40 – 16:45 Q&A

16:45 – 17:00

Targeting CD30 with monoclonal antibody-
based constructs

Anas Younes (New York, USA)

17:00 – 17:05 Q&A

17:05 – 17:20

Current success and future opportunities with
targeted therapy in Hodgkin Lymphoma

Peter Borchmann (Cologne, D)

17:20 – 17:25 Q&A

17:25 – 17:30

Closing comments

Andreas Engert (Cologne, D)



Opening Ceremony

Gürzenich Congress Center | 18:00 – 20:00

Bonadonna Lecture* Gürzenich, Großer Saal

The Hodgkin puzzle: Are we getting close?

Klaus Rajewsky (Berlin, D)

Awards Ceremony Gürzenich, Großer Saal

Get Together

Gürzenich Congress Center | 20:00

Gürzenich, Basement

Monday, 14.10.2013

Satellite Symposium (Roche Pharma GmbH)

07:30 – 08:30

Beyond the revolution of MabThera

Andreas Engert (Cologne, D) Gürzenich, Großer Saal

07:30 – 07:55

Do we have a new backbone in CLL?

Michael Hallek (Cologne, D)

07:55 – 08:20

Can we make MabThera better?

Andrew Davies
(Southampton, UK)

*This lecture is dedicated to Gianni Bonadonna

Session 3

08:30 – 10:00

Biology and Microenvironment **Gürzenich, Großer Saal**

Margaret Shipp (Boston, USA), Harald Stein (Berlin, D)

08:30 – 08:50

Microenvironment in Hodgkin Lymphoma

Randy Gascoyne
(Vancouver, CDN)**08:50 – 09:10**

Molecular pathogenesis of Hodgkin Lymphoma

Martin Janz (Berlin, D)

09:10 – 09:30

Deregulation of differentiation in pathogenesis of cHL

Thomas Wirth (Ulm, D)

09:30 – 09:40 | T049Plasma microRNA are disease response biomarkers in classical Hodgkin Lymphoma *Kimberley Jones (Brisbane, AUS)***09:40 – 09:50 | T050**CD57+ T cells in nodular lymphocyte predominant Hodgkin Lymphoma are T-follicular helper cells *Ahmad Sattarzadeh (Groningen, NL)***09:50 – 10:00 | T051**Analysis of myeloid suppressor marker Arginase identifies CD68+ / Arginase+ myeloid / monocytic subsets and exerts stronger prognostic influence than macrophage quantification in Classical Hodgkin Lymphoma *Andrea Gallamini (Cuneo, I)*

Session 4

10:30 – 12:00

Early Stages **Gürzenich, Großer Saal**

Aaron Polliack (Jerusalem, IL), Richard Hoppe (Stanford, USA)

10:30 – 10:50

Update on the NCRI RAPID trial

John Radford
(Manchester, UK)**10:50 – 11:10**

An update on the EORTC / LYSA / FIL H10 trial

Marc André (Yvoir, B)

11:10 – 11:30

WS report and further optimization in early stage Hodgkin Lymphoma

Andreas Engert
(Cologne, D)**11:30 – 11:40 | T033**Impact of bleomycin and dacarbazine within the ABVD regimen in the treatment of early-stage favorable Hodgkin Lymphoma: Final results of the GHSG HD13 trial *Karolin Behringer (Cologne, D)***11:40 – 11:50 | T034**Definition of bulky disease in early stage Hodgkin Lymphoma in computed tomography era: Prognostic significance of measurements in the coronal and transverse planes *Anita Kumar (New York, USA)***11:50 – 12:00 | T035**Brentuximab vedotin plus AVD as initial therapy of non-bulky limited stage classical Hodgkin Lymphoma: Interim analysis of an ongoing phase II trial *Jeremy S. Abramson (Boston, USA)*Lunch Symposium
(Teva GmbH)

12:15 – 13:45

NHL and G-CSF – Focus on optimising the resultsHelmut Ostermann (Munich, D) **Gürzenich, Großer Saal**

Introduction “Let’s get interactive”

Helmut Ostermann
(Munich, D)

Do we need G-CSF in Lymphoma Therapy?

Wolfgang Knauf
(Frankfurt, D)
Norbert Schmitz
(Hamburg, D)

How much G-CSF is necessary in Lymphoma Therapy?

Hartmut Link
(Kaiserslautern, D)

Current clinical Lymphoma trials based on G-CSF

Jens Hasskarl (Freiburg, D)

Innovation and Best Practice – how to benefit

Helmut Ostermann
(Munich, D)

Session 5

14:00 – 15:30

Hodgkin Lymphoma in older patients **Gürzenich, Großer Saal**

Magnus Björkholm (Stockholm, S), Andrew Lister (London, UK)

14:00 – 14:20

Epidemiology and biology

Magnus Björkholm
(Stockholm, S)**14:20 – 14:40**

First line treatment

Stephen J. Proctor
(Newcastle upon Tyne, UK)**14:40 – 15:00**

Relapsed / refractory Hodgkin Lymphoma in older patients

Boris Böll
(Cologne, D)**15:00 – 15:10 | T076**GHSG phase I / II trial of AVD-Rev (adriamycin, vinblastin, dacarbazine and lenalidomide) for older Hodgkin Lymphoma patients *Boris Böll (Cologne, D)***15:10 – 15:20 | T077**Sequential brentuximab vedotin (BV) and adriamycin, vinblastine, and dacarbazine (AVD) for older patients with untreated Hodgkin Lymphoma (HL): Preliminary toxicity findings from a phase II window study *Andrew M. Evens (Worcester, USA)***15:20 – 15:30 | T078**Treatment outcome in 111 elderly patients with Hodgkin Lymphoma: a retrospective analysis *Aspasia Stamatoullas (Rouen, F)*

PET and prediction **Gürzenich, Großer Saal**

Bertrand Coiffier (Lyon, F), Andrea Gallamini (Cuneo, I)

15:45 – 16:05
PET for early response prediction Martin Hutchings (Copenhagen, DK)**16:05 – 16:25**
PET review in GHSG trials Markus Dietlein (Cologne, D)**16:25 – 16:45**
PET in relapsed or refractory Hodgkin Lymphoma Craig Moskowitz (New York, USA)**16:45 – 16:55 | T108**
Response-adapted therapy of stage III–IV Hodgkin lymphoma based on interim FDG–PET imaging: early results of US intergroup S0816
*Oliver Press (Seattle, USA)***16:55 – 17:05 | T109**
Very early response as measured by (18F)–fluorodeoxyglucose–positron emission tomography (FDG–PET) after one cycle of chemotherapy in newly diagnosed pediatric / adolescent low risk Hodgkin Lymphoma (HL)
*Frank G. Keller (Atlanta, USA)***17:05 – 17:15 | T110**
Tailored therapy in Hodgkin Lymphoma, based on predefined risk factors and early interim PET / CT, Israeli H2 protocol: Preliminary report on 317 patients
*Eldad J. Dann (Haifa, IL)***Dinner Symposium** **17:45 – 19:15**
(prIME Oncology, supported by Millennium / Takeda)**Defining Therapeutic Targets in T-Cell Lymphoma**Bertrand Coiffier (Lyon, F) **Gürzenich, Großer Saal****17:45 – 17:50**
Welcome and Introduction Bertrand Coiffier (Lyon, F)**17:50 – 18:10**
Traditional approaches to T-cell Lymphoma Julie Vose (Omaha, USA)**18:10 – 18:15 Q&A****18:15 – 18:35**
Transition with targeted agents in T-cell Lymphoma Bertrand Coiffier (Lyon, F)**18:35 – 18:40 Q&A****18:40 – 19:00**
Targeting CD30 in T-cell Lymphoma Tim Illidge (Manchester, UK)**19:00 – 19:05 Q&A****19:05 – 19:15**
Challenging the experts: An interactive panel discussion Faculty Panel**19:15 Adjourn****Pediatric open session****07:30 – 09:00****Beyond the International Harmonization Criteria – New challenges in the application of imaging techniques for staging and response****Gürzenich, Großer Saal**Judith Landman–Parker (Paris, F), Kara Kelly (New York, USA),
Andreas Engert (Cologne, D)**07:30 – 07:50**
Practical experience in the application of the International Harmonization Criteria – as viewed by a medical oncologist Anas Younes (New York, USA)**07:50 – 08:10**
Anatomic imaging challenges of the International Harmonization Criteria Lawrence H. Schwartz (New York, USA)**08:10 – 08:30**
Nuclear medicine aspects of the International Harmonization Criteria, as they apply to pediatrics Regine Kluge (Leipzig, D)**08:30 – 08:50**
Overview of the challenges encountered by the Pediatric International Harmonization Criteria Workshop Kara Kelly (New York, USA)**08:50 – 09:00**
Discussion Dieter Koerholz (Halle, D)**Session 7****09:00 – 10:30****Survivorship** **Gürzenich, Großer Saal**

Lena Specht (Copenhagen, DK), Jonathan Friedberg (Rochester, USA)

09:00 – 09:20
Cardiac toxicity Judith Landman–Parker (Paris, F)**09:20 – 09:40**
Breast Cancer and other Neoplasms Berthe Aleman (Amsterdam, NL)**09:40 – 10:00**
Fertility Karolin Behringer (Cologne, D)**10:00 – 10:10 | T153**
Changes in breast cancer risk as long-term Hodgkin Lymphoma survivors reach menopausal age *Julia S. Wong (Boston, USA)***10:10 – 10:20 | T154**
Second cancer risk forty years after cure for Hodgkin Lymphoma
*Michael Schaapveld (Amsterdam, NL)***10:20 – 10:30 | T155**
A Dutch nationwide survivorship care programme for Hodgkin Lymphoma survivors *Flora van Leeuwen (Amsterdam, NL)*

Session 8

11:00 – 12:30

Advanced stages **Gürzenich, Großer Saal**

Franck Morschhauser (Lille, F), Richard Fisher (Rochester, USA)

11:00 – 11:20Risk-adapted therapy in advanced stage
Hodgkin Lymphoma: An UpdateMassimo Federico
(Modena, I)**11:20 – 11:40**

Can we improve ABVD?

Stephen Ansell
(Rochester, USA)**11:40 – 12:00**

Can we improve BEACOPP?

Peter Borchmann
(Cologne, D)**12:00 – 12:10 | T001**Impact of dose reductions of bleomycin and vincristine in patients with advanced Hodgkin Lymphoma treated with BEACOPP polychemotherapy: A comprehensive analysis of the German Hodgkin Study Group (GHSg) HD12 and HD15 trials *Bastian von Tresckow (Cologne, D)***12:10 – 12:20 | T002**Standard ABVD vs. escalated BEACOPP in stage III – IV low risk Hodgkin Lymphoma (IPS 0–2): the Lymphoma Study Association (LYSA) H34 trial *Nicolas Mounier (Nice, F)***12:20 – 12:30 | T003**Response rates and toxicity of response-adapted therapy in advanced Hodgkin Lymphoma: initial results from the international RATHL study *Peter Johnson (Southampton, UK)***Lunch Symposium**
(MSD Sharp & Dohme GmbH)

12:45 – 14:15

Update on Infectious Diseases in Hematology PatientsOliver A. Cornely (Cologne, D) **Gürzenich, Großer Saal****12:45 – 12:50**

Introduction

12:50 – 13:15Clinical infectious challenges in patients
with Hodgkin Lymphoma

Livio Pagano (Rome, I)

13:15 – 13:40Present and upcoming vaccines for the
immunocompromised host

Per Ljungman (Stockholm, S)

13:40 – 14:05Focussing on unmet medical needs in
abdominal infectionsMaria J. Vehreschild
(Cologne, D)**14:05 – 14:15**

Discussion and Summary

Faculty / O. A. Cornely

**Poster Walk** **Gürzenich, Kleiner Saal**

13:45 – 14:15

Please join the poster presentation and take the chance to discuss the results with our colleagues.

Session 9

14:30 – 16:00

Relapsed **Gürzenich, Großer Saal**

Christian Gisselbrecht (Paris, F), Anna Sureda (Barcelona, E)

14:30 – 14:50

What's new in relapsed Hodgkin Lymphoma?

Bastian von Tresckow
(Cologne, D)**14:50 – 15:30**Debate: Is there still a role for allogeneic
TX in Hodgkin Lymphoma?

Patrice Carde (Villejuif, F)

Pro:
Contra:Karl Peggs (London, UK)
Anton Hagenbeek
(Amsterdam, NL)**15:30 – 15:40 | T126**

Phase 2 study everolimus for relapsed / refractory classical Hodgkin Lymphoma (cHL)

*Patrick B. Johnston (Rochester, USA)***15:40 – 15:50 | T127**

Outcome of patients treated with autologous stem-cell transplantation for first relapsed or refractory Hodgkin Lymphoma: A long-term analysis of the prospective LYSA / SFGM-TC H96 trial

*David Sibon (Paris, F)***15:50 – 16:00 | T128**

PET adapted sequential salvage therapy with brentuximab vedotin and augmented ICE for transplant eligible patients with relapsed and refractory Hodgkin Lymphoma

Alison Moskowitz (New York, USA)

Milestones in Hodgkin Lymphoma **Gürzenich, Großer Saal**

Franco Cavalli (Bellinzona, CH), James Armitage (Omaha, USA)

16:15 – 16:30

Pathology

Harald Stein (Berlin, D)

16:30 – 16:45

Basic research

Stephan Mathas (Berlin, D)

16:45 – 17:00

Prognostic indices and PET

Bruce Cheson
(Washington, USA)**17:00 – 17:15**

Radiotherapy

Richard Hoppe
(Stanford, USA)**17:15 – 17:30**

Clinical trials

Volker Diehl (Cologne, D)

17:30 – 17:45

New drugs

Anas Younes (New York, USA)

18:00 – 18:30

Closing Remarks **Gürzenich, Großer Saal**

Andreas Engert (Cologne, D)

Poster Presentations

Posters will be displayed for viewing in the “Kleiner Saal” on Monday (October 14th) and Tuesday (October 15th).

1. Advanced Stages

Poster presenters are kindly asked to be present at their poster boards during the Posterwalk on Tuesday, October 15th, 13:45 to 14:15 to discuss their research.

Selected for Oral Presentations

T001

Impact of dose reductions of bleomycin and vincristine in patients with advanced Hodgkin Lymphoma treated with BEACOPP polychemotherapy: A comprehensive analysis of the German Hodgkin Study Group (GHSg) HD12 and HD15 trials
von Tresckow B, Haverkamp H, Böll B, Eichenauer DA, Sasse S, Fuchs M, Borchmann P, Engert A

T002

Standard ABVD vs. escalated BEACOPP in stage III – IV low risk Hodgkin Lymphoma (IPS 0–2): the Lymphoma Study Association (LYSA) H34 trial
Mounier N, Brice P, Bologna S, Briere J, Gaillard I, Voillat L, Gabarre J, Casasnovas O, Jaubert J, Colin P, Devidas A, Coiffier B, Aoudjhane A, Audhuy B, Carde P, Andre M

T003

Response rates and toxicity of response-adapted therapy in advanced Hodgkin Lymphoma: initial results from the international RATHL study
Johnson P, Federico M, Fossa A, Barrington S, Kirkwood A, Roberts T, Trotman J, Berkahn L, Enblad G, d'Amore F, Smith P, Radford J, Sun HW, Adams LG, Hewitt SM, Wilson WH, Pittaluga S, Meltzer PS, Staudt LM, Emmert-Buck MR, Jaffe ES

P004

First-line treatment of advanced stage Hodgkin Lymphoma – Final results of a systematic review and network meta-Analysis
Borchmann P, Rancea M, Skoetz N, Trelle S, Haverkamp H, Engert A

P005

Frontline Therapy with Brentuximab Vedotin Combined with ABVD or AVD in Patients with Newly Diagnosed Advanced Stage Hodgkin Lymphoma
Ansell SM, Connors JM, Park SI, O'Meara M, Younes A

P006

Early Treatment Intensification in Advanced-Stage High-Risk Hodgkin Lymphoma (HL) Patients, with a Positive FDG-PET Scan After Two ABVD Courses – Second Interim Analysis of the GITIL / FIL HD0607 Clinical Trial
Gallamini A, Rossi A, Patti C, Picardi M, Di Raimondo F, Cantonetti M, La Nasa G, Viviani S, Bolis S, Trentin L, Olivieri A, Zoli V, Biggi A, Chauvie S, Fiore F, Borra A, Prosperini Pharm G, Cavazzina R, Marchioli R, Parvis G, Zanotti R, Gavarotti P, Doderio A, Schiavotto C, Ciceri F, Avigdor A, Mulè A, Tarella C, Gianni AM, Rambaldi A

P007

Relapse analysis of irradiated patients within the HD15 trial of the German Hodgkin Study Group
Kriz J, Reinartz G, Kobe C, Kuhnert G, Haverkamp H, Haverkamp U, Hegerfeld K, Baues C, Engert A, Eich HT

P008

Characteristics and outcome of HIV associated Hodgkin Lymphoma among 59 patients included in the French ANRS C016 lymphovir cohort study
Besson C, Prevot S, Hendel-Chavez H, Lancar R, Génin M, Trabelsi S, Marchand L, Meyohas MC, Marchou B, Gabarre J, Bonnet F, Goujard C, Boué F, Mounier N, Partisani M, Raffi F, Costello R, Raphael M, Taoufik Y, Costagliola D

P009

Prognostic impact of CD20 expression in advanced stage classical Hodgkin's Lymphoma (CHL) treated with ABVD chemotherapy: a retrospective analysis
Sengar M, Sridhar E, Menon H, Dangi U, Shet T, Gujral S, Jain H, Laskar S, Khanna N

P010

Prospective Evaluation of the Utility of the International Prognostic Score (IPS) for Patients with Advanced Hodgkin Lymphoma (HL) Treated with Contemporary Therapy: Results from US Inter-group Trial E2496
Diefenbach CS, Li H, Hong F, Gordon LI, Fisher RI, Bartlett NL, Crump M, Gascoyne RD, Wagner H, Stiff PJ, Cheson BD, Stewart D, Kahl BS, Friedberg JW, Blum KA, Habermann TM, Tusciano JM, Hoppe RT, Horning SJ, Advani RH

P011

A pilot study of a reduced therapy driven by early PET response in 64 patients treated with 2 cycles of BEACOPPesc for advanced Hodgkin Lymphoma
Deau B, Franchi P, Briere J, Ohana J, Thieblemont C, Brice P

P012

High incidence of aseptic hip necrosis in Hodgkin Lymphoma patients treated with escalated BEACOPP with methyl-prednisolone
Basic-Kinda S, Durakovic N, Karlak I, Lubina ZI, Radman I, Dotlic S, Hude I, Aurer I

P013

Treatment results of six cycles EACOPP-14 ±RT in advanced stage Hodgkin Lymphoma. Multicenters study in Russia
Demina EA, Tumyan GS, Stroyakovskiy DL, Ryabukhina YE, Kuliev RG, Leontyeva AA, Profatilo IV, Ovchinnikova EG, Minenko SV, Biyachuev ER, Strelnikova TB, Nyashin VE, Yurchenkov AN, Larina YV, Trofimova OP, Sotnikov VM, Larioniva VB, Osmanov EA

P014

Peripheral blood lymphocyte / monocyte ratio in advanced stage classical Hodgkin Lymphoma: prognostic value and correlation with IPS and tumor associated macrophages

Jakovic LR, Andjelic BM, Bogdanovic AD, Perunicic Jovanovic MD, Babic D, Bumbasirevic VZ, Mihaljevic BS

P015

Bevacizumab added to ABVD for the treatment of advanced stage classical Hodgkin Lymphoma

Barnes JA, Hochberg EP, Takvorian T, Feng Y, Sohani A, Neuberg D, Abramson JS

P016

Early salvage with high-dose chemotherapy and stem cell transplantation in advanced stage Hodgkin's Lymphoma patients with positive positron emission tomography after two courses of chemotherapy: preliminary results of the IIL-HD0801 study

Zinzani PL, Bonfichi M, Rossi G, Zaja F, Vitolo U, Pavone V, Pulsoni A, Rigacci I, Gaidano G, Santoro A, Stelitano C, Rusconi C, Castagna L, Zaccaria A, Fattori PP, Liberati AM, Freilone R, Petti MC, Molinari A, Spina M, Latte G, Gioia D, Ferranti A, Ciccone G, Evangelista A, Castagnoli A, Riccardi U, Levis A

P017

Phase 3 study of brentuximab vedotin plus doxorubicin, vinblastine and dacarbazine (A+AVD) vs doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) as front-line treatment for advanced classical Hodgkin Lymphoma (HL): The ECHELON-1 study

Radford J, Younes A, Ansell SM, Gallamini A, Kim WS, Feldman TA, Hamadani M, Chung J, Wang J, Huebner D, Connors JM

P018

Results of treatment of Hodgkin Lymphoma in pregnant women

Sharkunov NN, Moiseeva TN, Al'-Radi LS, Zybunova EE, Shmakov RG, Kravchenko SK

P019

Substitution of Cyclophosphamide for Nitrogen Mustard in the Stanford V (SV) Regimen Does Not Compromise Outcome in Adults with Hodgkin Lymphoma

Advani RH, Varma G, Horning SJ, Allen J, Rosenberg SA, Hoppe RT

P020

BEACOPP-14 in 299 patients with advanced-stage Hodgkin Lymphoma: a single center results

Moiseeva TN, Sharkunov NN, Al-Radi LS, Zybunova EE, Chernova NG, Margolin OV, Maryin DS, Julakyan UL, Melikyan AL, Mangasarova YK, Skidan NI, Tseytlina MA, Shitareva IV, Tsyba NN, Kravchenko SK

P021

Nodular lymphocyte predominant Hodgkin Lymphoma with bone marrow involvement

Khilavno AB, Moiseeva TN, Kovrigina AM, Al-Radi LS, Sharkunov NN, Kravchenko SK

P022

Long-term results of risk-adapted therapy for advanced Hodgkin's Lymphoma: one-center experience (1998-2012)

Bogatyreva TI, Pavlov VV

P023

Intensified BEACOPP therapy for newly diagnosed patient with advanced stages classical Hodgkin's Lymphoma

Kriachok I, Novosad O, Titorenko I, Filonenko K, Aleksik E, Kadnikova T, Gubareva A, Kushchevov E, Martynchyk A, Pastushenko Y, Ulyanchenko K, Stepanishyna I

P024

Bone marrow involvement in Classical and Nodular Lymphocyte Predominant Hodgkin Lymphoma – Indian tertiary cancer centre experience

Epari S, Sengar M, Gujral S, Menon H, Laskar S, Shet T

P025

Comparison of demographic characteristics of Hodgkin's Lymphoma from two prospective registries in Brazil and Italy
Biasoli I, Luminari S, Castro N, Delamain M, Bellei M, Gaiolla R, Cesaretti M, Simões B, Lachetta F, Solza C, Praxedes M, Sola CB, Baiocchi O, Chiattoni C, de Souza C, Spector N, Federico M

P026

Extranodal dissemination in classical Hodgkin Lymphoma. Real unfavourable disease
Jakovic LR, Andjelic BM, Bogdanovic AD, Perunicic Jovanovic MD, Bumbasirevic VZ, Mihaljevic BS

P027

Hodgkin's Lymphoma presenting with pulmonary cavitations
Praxedes Lusi MK, Nucci FM, Lusi LKP, Mercante DR, Orlando EP, Aide MA, Carvalho JEM, Figueira CFN, Monnerat AC, Teixeira GNC, Pires ARC, Dias LVB

P028

Therapeutic response of Tunisian national protocol: experience of two centers
Kacem K, Zriba S, Ghédira H, Yahyaoui Y, Mansouri R, Dridi M, Hadj Mansour M, Manai Z, Zarrouk M, Ben Neji H, Ben Abdennebi Y, Jeddi R, Aissaoui L, Belhadj Ali Z, Ben Abid H, M'Sadek F, Ben Lakhal R, Meddeb B.

P029

The differences in risk profile of male and female patients with advanced Hodgkin's Lymphoma
Andjelic B, Jakovic L, Antic D, Todorovic M, Bila J, Sretenovic A, Djurasinovic V, Mihaljevic B

P030

The identification of high risk ABVD treated advanced Hodgkin's Lymphoma patients – IPS remains the most appropriate prognostic tool
Andjelic B, Antic D, Jakovic L, Todorovic M, Bogdanovic A, Bila J, Mihaljevic B

P031

Lower dose intensity chemotherapy; impact on treatment outcome and survival of patients with advanced Hodgkin Lymphoma: Single institution experience
Tomasevic Z, Tomasevic Z.

P032

Diagnostical challenges in our adolescent patient with Lymphoma
Magyari F, Rajnai H, Barna S, Miltényi Z, Váróczy L, Csomor J, Illés A

2. Early Stages

Poster presenters are kindly asked to be present at their poster boards during the Posterwalk on Tuesday, October 15th, 13:45 to 14:15 to discuss their research.

Selected for Oral Presentations

T033

Impact of bleomycin and dacarbazine within the ABVD regimen in the treatment of early-stage favorable Hodgkin Lymphoma: Final results of the GHSG HD13 trial
Behringer K, Goergen H, Borchmann P, Diehl V, Fuchs M, Hitz F, Zijlstra JM, Greil R, Markova J, Topp MS, Soekler M, Mathas S, Meissner J, von Tresckow B, Böll B, Engert A

T034

Definition of Bulky Disease in Early Stage Hodgkin Lymphoma in Computed Tomography Era: Prognostic Significance of Measurements in the Coronal and Transverse Planes
Kumar A, Burger IA, Zhang Z, Maragulia J, Yahalom J, Moskowitz CH, Zelenetz AD

T035

Brentuximab vedotin plus AVD as initial therapy of non-bulky limited stage classical Hodgkin Lymphoma: Interim analysis of an ongoing phase II trial

Abramson JS, Hochberg EP, Joyce R, Avigan D, Bello CM, LaCasce AS, Feng Y, Neuberg D, Takvorian T, Barnes JA, Arnason JE

Posters**P036**

Infradiaphragmatic Hodgkin Lymphoma in patients treated with state-of-the-art therapies: A risk factor analysis from the German Hodgkin Study Group (GHSg) HD13 and HD14 trials
von Tresckow B, Görgen H, Plütschow A, Böll B, Eichenauer DA, Sasse S, Rothe A, Fuchs M, Behringer K, Engert A, Borchmann P

P037

Impact of dose intensification on the outcome in early-stage unfavorable HL: 7-year follow-up analysis of the GHSg HD14 trial
Sasse S, von Tresckow B, Plütschow A, Fuchs M, Klimm B, Markova J, Hitz F, Kral Z, Greil R, Topp MS, Meissner J, Zijlstra JM, Soekler M, Eich HT, Borchmann P, Engert A

P038

Prognostic performance of pre-treatment EORTC, GHSg and IPI risk factors and post-chemotherapy PET response in the UK NCRI RAPID trial in early stage Hodgkin Lymphoma (HL)
Radford J, Barrington S, Counsell N, Pettengell R, Johnson P, Wimpey J, Coltart S, Culligan D, Lister A, Bessell E, Kruger A, Hancock B, Hoskin P, O'Doherty M, Illidge T

P039

Image-Guided Intensity Modulated Radiotherapy vs. Standard 3D-Conformal Radiotherapy in Early Stage Hodgkin's Lymphoma
Filippi AR, Ciammella P, Piva C, Ragona R, Botto B, Gavarotti P, Merli F, Vitolo U, Lotti C, Ricardi U

P040

Local control in stage I-II Hodgkin Lymphoma: Patterns of failure analysis in cohort treated with modern technique

Skliarenko J, Lao L, Gospodarowicz M, Pintilie M, Hodgson D, Sun A, Kukreti V, Kuruvill J, Crump M, Tsang R

P041

Doses to head and neck normal tissues after radiotherapy for early stage Hodgkin Lymphoma

Maraldo MV, Brodin NP, Aznar MC, Vogelius IR, Munck af Rosenschöld P, Petersen PM, Specht L

P042

Deep inspiration breathhold radiation therapy reduces radiation dose to cardiac structures in patients treated for mediastinal Hodgkin Lymphoma

Petersen PM, Aznar MC, Berthelsen AK, Loft A, Schut DA, Maraldo M, Klausen TL, Andersen F, Specht L

P043

The role of HIF signaling in the reprogramming of HRS cells
Wein F, Otto T, Fandrey J, Küppers R

P044

Phase II study of involved node proton therapy for Stage I-III Hodgkin Lymphoma

Hoppe BS, Flampouri S, Su Z, Zaiden R, Ozdemir S, Slayton W, Sandler E, Dang N, Lynch J, Li Z, Mendenhall N

P045

ABVD without consolidation radiotherapy (RT) after complete remission (CR) in pediatric Hodgkin Lymphoma (HL): preliminary results of a pilot study

Terenziani M, Schiavello E, Crippa F, Cefalo G, Gandola L, Pecori E, Casanova M, Ferrari A, Luksch R, Meazza C, Polastri D, Spreafico F, Catania S, Biassoni V, Podda M, Chiaravalli S, Vajna de Pava M, Massimino M

P046

A response-based ABVD regimen with or without radiotherapy for pediatric low and intermediate risk Hodgkin Lymphoma in Central America and Dominican Republic, a report from AHOPCA
Castellanos M, Metzger M, Baez LF, Gamboa Y, Soad Alabi APHAP, Luna-Fineman S, Nieves R, de Alarcon P

P047

Influence of interplay effects due to breathing motion for proton spot scanning treatment of mediastinal Hodgkin Lymphoma
Norrliid O, Nilsson K, Bäck A, Sooruu M, Raunert I, Goldkuhl C, Molin D

P048

Comparative Characteristics of Radiotherapy (RT) Methods in Treatment of Hodgkin's Lymphoma (HL) with Mediastinal Lymph Nodes Involvement
Larinov DV

3. Biology and Microenvironment

Poster presenters are kindly asked to be present at their poster boards during the Posterwalk on Tuesday, October 15th, 13:45 to 14:15 to discuss their research.

Selected for Oral Presentations

T049

Plasma microRNA are disease response biomarkers in classical Hodgkin Lymphoma
Jones K, Nourse JP, Keane C, Bhatnagar A, Seymour L, Gandhi MK

T050

CD57+ T cells in nodular lymphocyte predominant Hodgkin's Lymphoma are T-follicular helper cells
Sattarzadeh A, Rutgers B, Diepstra A, van den Berg A, Visser L

T051

Analysis of myeloid suppressor marker Arginase identifies CD68+/Arginase+ myeloid / monocytic subsets and exerts stronger prognostic influence than macrophage quantification in Classical Hodgkin Lymphoma.
Gallamini A, Agostinelli C, Tripodo C, Starcqualursi L, Fuligni F, Fiore F, Rigacci L, D'Amore F, Merli F, Vitolo U, Patti C, Stelitano C, Di Raimondo F, Levis A, Trentin L, Kamper P, Piccaluga PP, Broccoli A, Zinzani PL, Pileri SA, on behalf of Danish Lymphoma Group and the Intergruppo Italiano Linfomi

Posters

P052

The CD30 / CD16A bispecific antibody TandAb AFM13 activates NK cells from Hodgkin Lymphoma patients resulting in specific tumor cell killing
Reiners KS, Kessler J, Sauer M, Rothe A, Hansen HP, Reusch U, Hücke C, Köhl U, Dürkop H, Engert A, Pogge von Strandmann E

P053

HLA Associated Susceptibility to EBV+ Hodgkin Lymphoma: No Correlation with Infectious Mononucleosis or Number of Circulating EBV+ B Cells
Diepstra A, Leese AM, Pachnio A, Bell AI, Hepkema B, van den Berg A, Moss P, Lee SP, Rickinson AB

P054

Promyelocytic leukemia nuclear bodies and special AT rich binding protein 1 are related to HLA class I and II expression in Hodgkin Reed-Sternberg cells
Liu Y, van den Berg A, Veenstra R, Rutgers B, van Imhoff G, Visser L, Diepstra A

P055

Long non-coding RNAs in Hodgkin Lymphoma
Tayari M, Kok K, Kortman G, Sietzema J, de Jong D, Terpstra M, Visser L, Diepstra A, Kluiver J, van den Berg A

P056

Immunosuppressive properties of myeloid cells in Hodgkin's Lymphoma

Romano A, Parrinello NL, Vetro C, La Cava P, Forte S, Chiarenza A, Motta G, Triolo A, Palumbo GA, Consoli U, Di Raimondo F

P057

Macrophages in T cell / histiocyte rich large B cell lymphoma strongly express metal-binding proteins and show a bi-activated phenotype

Hartmann S, Tousseyn T, Döring C, Flüchter P, Hackstein H, Herreman A, Ponzoni M, de Wolf-Peters C, Facchetti F, Gascoyne RD, Küppers R, Steidl C, Hansmann ML

P058

Circulating cell-free DNA as prognostic biomarker in Hodgkin Lymphoma: quantitative and qualitative evaluations

Giachelia M, Cupelli E, Cuccaro A, Massini G, Bartolomei F, Tisi MC, D'Alò F, Voso MT, Leone G, Hohaus S

P059

Prognostic value of CD68 count in the treatment of Hodgkin Lymphoma in the "PET era"

Cuccaro A, Calcagni ML, Rufini V, Massini G, Bartolomei F, Giachelia M, Cenci T, Martini M, D'Alò F, Balducci M, Leone G, Larocca LM, Hohaus S

P060

Clinical Significance of Tumor-Associated Macrophages in Early-Stage Hodgkin's Lymphoma

Gotti M, Nicola M, Fiaccadori V, Bono E, Lucioni M, Bonfichi M, Varettoni M, Pascutto C, Arcaini L, Paulli M, Cazzola M

P061

Regulatory T-cells detectable in peripheral blood in Hodgkin's Lymphoma increase during ABVD chemotherapy, except for patients with positive interim PET

Romano A, Parrinello NL, Vetro C, La Cava P, Chiarenza A, Motta G, Triolo A, Palumbo GA, Di Raimondo F

P062

Specific degradation pattern of peroxiredoxin 1 correlates with adverse outcome in classical Hodgkin Lymphoma patients

Ludvigsen M, Kamper P, Singers Soerensen B, Hamilton-Dutoit SJ, Bendix K, Møller MB, Alsner J, d'Amore FA, Honoré B

P063

Effect of the EBV+cHL risk allele HLA-A*01:01 upon EBV infected B-cell Frequency and the EBV-Specific Immune Response

McAulay KA, Farrell K, Lake A, Jarrett RF

P064

Inflammatory monocytes are increased in peripheral blood in Hodgkin's Lymphoma

Parrinello NL, Romano A, Vetro C, Triolo A, Di Raimondo F

P065

The number of tumor-infiltrating mast cells correlates with adverse prognosis in mixed cellularity, but not nodular sclerosis type, classical Hodgkin Lymphoma

Andersen MD, Kamper P, Nielsen P, Bendix K, Riber-Hansen R, Steinicke T, Hamilton-Dutoit S, Clausen M, d'Amore F

P066

Cell cycle dynamics of Hodgkin and Reed-Sternberg cells of classical Hodgkin Lymphoma at primary diagnosis and relapse assessed in vivo

Gontarewicz A, Vogt N, Klapper W

P067

Spindle shaped CD163+ rosetting macrophages replace CD4+ T cells in HIV-related classical Hodgkin Lymphoma

Hartmann S, Jakobus C, Rengstl B, Döring C, Newrzela S, Brodt HR, Wolf T, Hansmann ML

P068

Hodgkin Lymphoma subtypes and peripheral lymphopenia are associated with EBV status in children and adolescents in France: A preliminary report of the EuroNet LH EPI project
Besson C, Boudjema S, Hamdi L, Creidy R, Leblanc T, Lambilliotte A, Dainese L, Doukoure B, Krzysiek R, Coulomb A, Landman-Parker J

P069

Serum TARC levels in a cohort of pediatric patients with Hodgkin Lymphoma (HL): a promising biomarker?
Schiavello E, Terenziani M, Mazzocchi A, Casanova M, Ferrari A, Luksch R, Meazza C, Polastri D, Spreafico F, Catania S, Biasson V, Podda M, Chiaravalli S, Vajna de Pava M, Massimino M

P070

Prognostic significance of CD68, CD20, FOXP3 expression; presence of Epstein-Barr virus and mast cell infiltration in classical Hodgkin Lymphoma patients
Salihoglu A, Ozbalak M, Demiroz AS, Tuzuner N, Elverdi T, Gulturk E, Eskazan AE, Ar MC, Ongoren S, Baslar Z, Soysal T, Aydin Y, Ferhanoglu B

P071

MultiOmyx™: Novel Chemistry and Visualization Tools to Aid Resolution of Discrepant Hodgkin Lymphoma Cases
Adams A, Bordwell A, Bouman D, Fisher D, Hollman D, Lazare M, Li M, Ross AS, Weiss LM

P072

Effects of the NF- κ B inhibitors bortezomib and DHMEQ on the expression of molecules involved in microenvironmental interactions and synergy with chemotherapy agents
Celegato M, Borghese C, Casagrande N, Umezawa K, Colombatti A, Carbone A, Aldinucci D

P073

Relationship between Epstein-Barr Virus latency in pediatric Hodgkin Lymphoma and immunological status of the host
Klekawka T, Balwierz W

P074

Interleukin IL-12B in pediatric patients with Hodgkin's Lymphoma in the state of Pernambuco, Brazil
Moraes A, Ferreira de Barros T, Ferreira FS, Gomes AV, Ortolan M, Cartaxo Muniz MT, do Socorro de Mendonça Cavalcanti M

P075

Interleukin IL-28B polymorphism in pediatric patients with Hodgkin's Lymphoma in the state of Pernambuco, Brazil
Cartaxo Muniz MT, de Barros TF, Ferreira FS, Gomes AV, Moraes A, do Socorro de Mendonça Cavalcanti M

4. HL in older patients

Poster presenters are kindly asked to be present at their poster boards during the Posterwalk on Tuesday, October 15th, 13:45 to 14:15 to discuss their research.

Selected for Oral Presentations

T076

GSHS phase I/II trial of AVD-Rev (Adriamycin, Vinblastin, Dacarbacin and Lenalidomide) for older Hodgkin Lymphoma patients
Böll B, Plütschow A, Fuchs M, Thielen I, Eichenauer DA, von Tresckow B, Behringer K, Engert A, Borchmann P

T077

Sequential Brentuximab Vedotin (BV) and Adriamycin, Vinblastine, and Dacarbazine (AVD) for Older Patients with Untreated Hodgkin Lymphoma (HL): Preliminary Toxicity Findings from a Phase II Window Study
Evens AM, Hamlin PA, Advani RH, Fanale M, Smith SM, Bociek G, Fenske TS, Petrich A, Winter J, Gordon L

T078

Treatment outcome in 111 elderly patients with Hodgkin Lymphoma: a retrospective analysis
Stamatoullas A, Bertrand P, Cassuto O, Chamseddine A, Groza L, Lenain P, Lepretre S, Lanic H, Lemasle E, Jardin F, Contentin N, Picquenot JM, Bastard C, Tilly H

Posters**P079**

Pulmonary lethality associated with Bleomycin in ABVD chemotherapy for first-line Hodgkin Lymphoma (HL) treatment
Arar A, Malphettes M, Bergeron A, Azoulay E, Brice P

P080

ABVD Therapy in Older Patients with Hodgkin Lymphoma: Response and Complications
Johnston PB, Yin J, Micallef INM

P081

Hodgkin Lymphoma in patient with angioimmunoblastic T-cell lymphoma
Chernova NG, Sidorova JV, Margolin OV, Mariyin DS, Al-Radi LS, Moiseeva TN, Kovrigina AM, Kremenetskaya AM, Vorobiev AI, Kravchenko SK

5. Pathways

Poster presenters are kindly asked to be present at their poster boards during the Posterwalk on Tuesday, October 15th, 13:45 to 14:15 to discuss their research.

Selected for Oral Presentations**T082**

Disruption of B cell differentiation by conditional activation of the Hodgkin Lymphoma-associated E2A antagonists Id2 and Abf1 in vivo
Janz M, Li S, Calado DP, Mathas S, Dörken B, Rajewsky K

T083

Integrated Genomic Analysis of Flow Sorted Hodgkin and Reed-Sternberg Cell in Primary Classical Hodgkin Lymphoma
Reichel J, Cesarman E, Radaban R, Elemento O, Shaknovich R, Roshal M

T084

TCF3 / E2A (19p13.3) is a novel Hodgkin Lymphoma susceptibility locus; a meta-GWAS study from the InterLymph Hodgkin Lymphoma consortium
Van den Berg A, Cozen W, Li D, Timofeeva M, Diepstra A, Hazelet D, Delahaye-Sourdeix M, Edlund CK, Rostgaard K, van den Berg DJ, Glaser SL, Robison LL, Mack TM, Ghesquieres H, Salle G, Bhatia S, Strong LC, Hwang AE, Nieters A, Smedby K, de Sanjose S, Cortessis VK, Lightfoot T, Roman E, Becker N, Foretova L, Benavente Y, Maynadie M, Visser L, Veenstra RN, Staines A, Cocco PL, Boffetta P, Kiemeny L, Lake A, Montgomery D, Slager SL, Cerhan JR, Gallagher A, Taylor GM, Brennan P, Conti DV, Coetzee GA, Onel K, Jarrett RF, Hjalgrim H, McKay JD

T085

Hodgkin-Reed-Sternberg cells in classical Hodgkin Lymphoma show alterations of genes encoding the NADPH oxidase complex and impaired reactive oxygen species synthesis capacity
Giefing M, Winoto-Morbach S, Sosna J, Döring C, Klapper W, Küppers R, Böttcher S, Adam D, Siebert R Stefan S

P086

Downregulation of FOXO1 prevents induction of the tumor suppressor PRDM1 in cHL

Vogel MJ, Xie L, Guan H, Kick A, Brüderlein S, Melo JV, Tooze RM, Ushmorov A, Wirth T

P087

Development of an original xenograft model of human Hodgkin Lymphoma: toward a better understanding of the pathology and the design of new therapies

M'kacher R, Frenzel M, Corina C, Bauchet A, Leunen A, Hempel W, Jinckel S, Girinsky T, Carde P, Boisgard R, Plumio FF, Sabatier L

P088

Specific bioenergetic adaptation of distinct B-cell lymphomas

Birkenmeier K, Dröse S, Wittig I, Winkelmann R, Barrera M, Hartmann S, Döring C, Völkl L, Wenz T, Reichert AS, Bereiter-Hahn J, Brandt U, Hansmann ML

P089

Genomic analysis of serial Hodgkin Lymphoma samples reveals driver mutated genes

Martin-Moreno AM, Mata E, Montalban C, Piris MA, Garcia JF

P090

The Novel Second Generation Proteasome Inhibitor MLN9708 in Hodgkin Lymphoma (HL) and T-Cell Lymphoma (TCL): Induction of Potent Cell Death through Redox, MAPK, and Autophagic-Dependent Mechanisms in Cell Lines and Human Lymphoma Xenograft Models

Dashnamoorthy R, Kandela I, Bhalla S, Zaretsky I, Galloway J, Mazar A, Evens AM

P091

Genome-wide Association Study Identifies Germline Polymorphisms Associated with Aggressive Disease and Treatment Response of Hodgkin Lymphoma

Yang JJ, Lim J, Lei Shi L, Stanley Pounds S, Jianrong Wu J, Melissa M Hudson MM, Metzger ML

P092

The impact of the GSTP1 A313G polymorphism on clinical outcome in Hodgkin's Lymphoma patients

Kryachok I, Khranovska N, Svergun N, Novosad O, Titorenko I

P093

Drug re-profiling in Hodgkin's Lymphoma identifies monoamine oxidase over-expression as a potential therapeutic target

Fairbanks JY, Nagy E, Khanim F, Wei W, Lu X, Bunce C, Drayson M, Murray PG

P094

Mechanisms of the "dedifferentiation" of the HRS cells in classical Hodgkin Lymphoma

Schneider M, Bräuninger A, Hansmann ML, Küppers R

P095

Modelling of HLA associations in EBV-positive and -negative classical Hodgkin Lymphoma suggests distinct mechanisms in disease pathogenesis

Johnson PCD, McAulay KA, Montgomery D, Lake A, Gallagher A, Taylor GM, Jarrett RF

P096

Studies on the signal transduction pathway involved in leukotriene D₄-induced release of cytokines from the Hodgkin Lymphoma Cell Line L1236

Han H, Xue-Franzén Y, Nagy E, Xu D, Sjöberg J, Björkholm M, Claesson HE

P097

HLA class II alleles are associated with tumor cell HLA class II expression in classical Hodgkin Lymphoma

Kushekhar K, Nolte I, Hepkema B, Veenstra R, Poppema S, Visser L, Diepstra A, van den Berg A.

P098

Procalcitonin (PCT) levels in newly diagnosed patients with Hodgkin Lymphoma (HL) presenting with fever and / or elevated c-reactive protein (CRP)

Vassilakopoulos TP, Zografos E, Petevi K, Boutsikas G, Kanellopoulos A, Hillas G, Dimou M, Gainaru G, Papageorgiou L, Sinni E, Kyrtsionis MC, Pappi V, Tsopra O, Tzenou T, Efthymiou A, Vardounioti I, Pessach E, Flevari P, Telonis V, Koutsi K, Zannou A, Papakostas V, Tsafaridis P, Plata E, Panayiotidis P, Beris Ph, Angelopoulou MK, Meletis J

P099

Classical Hodgkin Lymphoma and HHV-6: a reinvestigation of a causal association

Bell AJ, Gallagher A, Gatherer D, Jarrett RF

P100

Metabolites of arachidonic acid are involved in the pathophysiology of Hodgkin Lymphoma

Sjöberg J, Han H, Liu C, Xu D, Björkholm M, Claesson HE

P101

The role of microRNA in Hodgkin Lymphoma

Schmidt A, Döring C, Hansmann ML, Küppers R

P102

Treatment pathways and resource use associated with the management of recurrent Hodgkin Lymphoma after autologous stem cell transplantation

Radford J, Johnson R, McKay P, Malladi R, Peggs K, Sureda A, Bloor A, Kerrigan M, Ralston S, Cooper S, Uden R, Christensen K

P103

The novel Sirtuin inhibitor, As4.064 is active against Hodgkin Lymphoma Lines as Single Agent and in Combination with other Histone Deacetylase Inhibitors

Kirschbaum MH, Scata K, Sharma A, Desai D, Amin S

P104

The Ephrin and Ephrin-receptor families are widely expressed in Hodgkin Lymphoma

Veenstra R, de Jager W, van den Berg A, Diepstra A, Visser L

P105

Telomerase dependent and telomerase independent telomere maintenance mechanisms in Hodgkin Lymphoma

Cuceu C, Morat L, Lemain A, Shim G, Frenzel M, Ricoul M, Henpe W, Guileto E, Junker S, Girinsky T, Carde P, Delhem N, Sabatier L, M'kacher R

P106

Preliminary characterization of MHC polymorphisms as risk factors for pediatric and adult classical Hodgkin lymphoma in a region with early EBV seroconversion

Hassan R, Garcia A, Cohen M, Vera-Lozada G, Oliveira-Silva M, Segges P, Gantuz M, De Matteo E, Barros MH, Preciado MV, Chabay P

P107

Classical Hodgkin Lymphoma: Evaluation for B-cell clonality from formalin fixed paraffin embedded tissues

Epari S, Sengar M, Basak R, Gujral S, Menon H, Shet T

6. PET and prediction

Poster presenters are kindly asked to be present at their poster boards during the Posterwalk on Tuesday, October 15th, 13:45 to 14:15 to discuss their research.

Selected for Oral Presentations

T108

Response-adapted therapy of stage III–IV Hodgkin Lymphoma based on interim FDG–PET imaging: early results of us intergroup S0816

Press O, Li H, Schöder H, LeBlanc M, Rimsza L, Friedberg JW, Bartlett N, LaCasce A, Sweetenham J, Evens A, Straus D, Knopp M, Noy A, Hsi E, Cook J, Mittra E, Lechowicz MJ, Gascoyne RD, Miller TP, Kahl B, Cheson BD, Fisher RI

T109

Very Early Response as Measured by (18F)–fluorodeoxyglucose–Positron Emission Tomography (FDG–PET) After One Cycle of Chemotherapy in Newly Diagnosed Pediatric/Adolescent Low Risk Hodgkin Lymphoma (HL)

Keller FG, Nachman J, Castellino SM, Constine LS, Voss S, Thomson J, Dunphy C, McCarten KM, Chen L, Schwartz CS

T110

Tailored Therapy in Hodgkin Lymphoma, Based on Predefined Risk Factors and Early Interim PET/CT, Israeli H2 protocol: Preliminary Report on 317 Patients

Dann EJ, Bairey O, Bar-Shalom R, Izak M, Korenberg A, Akria L, Attias D, Filanovsky K, Abadi U, Ruchlemer R, Abdah–Bortnyak R, Goldschmidt N, Epelbaum R, Avivi I, Lavie D, Rowe JM, Shpilberg O, Paltiel O

Posters

P111

FDG PET–based parameters for total tumor burden at diagnosis are highly predictive for outcome in pediatric Hodgkin Lymphoma (HL): a COG AHOD0031 retrospective study

Chirindel A, Kim J, Chen L, Buxton A, Kessel S, Leal J, McCarten KM, Wolden SL, Schwartz CL, Friedman DL, Kelly KM, Cho SY

P112

The prognostic role of interim PET after first chemotherapy cycle in ABVD–treated Hodgkin Lymphoma (HL) patients– Polish Lymphoma Research Group (PLRG) Observational Study

Zaucha JM, Chauvie S, Małkowski B, Warszewska A, Biggi A, Kobylecka M, Danielewicz I, Tajer J, Subocz E, Kulikowski W, Dzietczenia J, Wojtowicz M, Romanowicz A, Kroll–Balcerzak R, Chamier–Ciemirńska A, Dziuk M, Mazurek A, Piwkowski P, Czepczyński R, Damico A, Bergesio F, Fallanca F, Lesniewski–Kmak K, Wróbel T, Walewski J, Gallamini A

P113

Upstaging by PET–ascertained bone and bone marrow involvement in Hodgkin Lymphoma – definitions matter

Borra A, El–Galaly TC, Zaucha JM, Rigacci L, Rapezzi D, Rago A, Bolis S, Gavarotti P, Rusconi C, Trentin L, Stelitano C, Biggi A, Gormsen LC, D'Amore F, Hutchings M, Gallamini A

P114

Comparative assessment of bone marrow involvement (BMI) by BM biopsy (BMB) or positron emission tomography/computed tomography (PET/CT) in Hodgkin Lymphoma (HL)

Vassilakopoulos TP, Angelopoulou MK, Prassopoulos V, Chatziioannou S, Moschogiannis M, Tsirkinidis P, Poziopoulos C, Symeonidis A, Repoussis P, Matsouka Ch, Kontopidou FN, Sotiropoulos V, Variami E, Viniou NA, Zikos P, Petevi K, Boutsikas G, Kanellopoulos A, Papageorgiou I, Panayiotidis P, Pangalis GA, Datseris I, Meletis J, Rondogianni Ph

P115

Pretreatment and Interim Tumor Burden by CT Predicts Event–Free Survival in Children and Adolescents with Hodgkin Lymphoma (HL): a COG AHOD0031 retrospective study

Kelly KM, Xie C, Chen L, Buxton A, Tan Y, Friedman DL, Schwartz CL, Zhao B, Schwartz L

P116

Stage migration in Hodgkin Lymphoma after the introduction of FDG–PET/CT

Enblad G, Jerkeman M, Raud C, Björkholm M, Goldkuhl C, Linderöth J, Lagerlöf I, Johansson AS, Molin D

P117

Evaluation of TARC and sCD163 as biomarkers in classical Hodgkin Lymphoma

Montgomery D, Tiplady E, Lake A, Crae S, Farrell K, McKay P, Jarrett RF

P118

Routine bone marrow evaluation in newly diagnosed Hodgkin Lymphomas staged with PET/CT: Is it really necessary? Experience of two Italian hematological centers

Puccini B, Volpetti S, Rigacci L, Zaja F, Kovalchuk S, Fabbri E, Chiozzotto M, Benelli G, Puglisi S, Mazzucco M, Perali G, Bosi A, Fanin R

P119

PET/CT in the setting of autologous stem cell transplantation (ASCT) for relapsed / refractory Hodgkin Lymphoma PET/CT in the setting of autologous stem cell transplantation (ASCT) for relapsed / refractory Hodgkin Lymphoma (HL): performance of various interpretation Systems

Angelopoulou MK, Moschogiannis M, Rondogianni P, Tsirkinidis P, Nikaki A, Chatziioannou S, Galani Z, Tsaftaridis T, Sachanas S, Telonis V, Flevari P, Petevi K, Zannou A, Datseris K, Prassopoulos V, Kyrtsionis M, Panayiotidis P, Meletis J, Pangalis G, Vassilakopoulos TP

P120

Gene expression profiles and prognostic associations in children and adolescents with classical Hodgkin Lymphoma

Vera-Lozada G, Segges P, Scholl V, Stefanoff CG, Barros MHM, Hassan R

P121

Interim and subsequent 18FDG-PET-CT determine the outcome of pediatric Hodgkin's Lymphoma

Zaghloul MS, Elhaddad A, Attia E, Omar W, Mohamed O, Elmenawy S

P122

Comparison of plasma TARC with Galectin-1 as biomarkers for response in classical Hodgkin Lymphoma

Plattel WJ, Van den Berg A, Van Imhoff GW, Diepstra A, Visser L

P123

Interim PET/CT in Hodgkin-Lymphoma- Final results of the hungarian CHEAP study (2007-2011)

Miltényi Z, Simon Z, Jóna A, Magyar F, Barna S, Garai I, Illés A and the CHEAP study group

P124

Utility of PET scan for early diagnosis of Bleomycin induced pneumonitis in Hodgkin's Lymphoma

Mittal S, Sengar M, Rangarajan V, Purandare N, Tandon S, Dangi U, Menon H

P125

Early evaluation of response by PET/TAC in patients diagnosed of Hodgkin Lymphoma in early and advanced disease

García Fera A, Escrivà A, Andreu R, Varzaru A, Ribas P, Fernández Llavador MJ, Sayas MJ, Fernández Zarzoso M, Juan ML, Cejalvo MJ, Pedreño M, Ros J, Tolosa A, Panero M, Ferrer S

7. Relapsed

Poster presenters are kindly asked to be present at their poster boards during the Posterwalk on Tuesday, October 15th, 13:45 to 14:15 to discuss their research.

Selected for Oral Presentations

T126

Phase 2 Study Everolimus for Relapsed / Refractory Classical Hodgkin Lymphoma (cHL)

Johnston PB, Pinter-Brown L, Rogerio J, Warsi G, White K, Ramchandren R

T127

Outcome Of Patients Treated With Autologous Stem-Cell Transplantation For First Relapsed Or Refractory Hodgkin Lymphoma: A Long-Term Analysis Of The Prospective LYSA / SFGM-TC H96 Trial
Sibon D, Resche-Rigon M, Morschhauser F, Fermé C, Dupuis J, Marçais A, Bouabdallah R, Sebban C, Salles G, Brice P

T128

PET adapted sequential salvage therapy with brentuximab vedotin and augmented ICE for transplant eligible patients with relapsed and refractory Hodgkin Lymphoma
Moskowitz AJ, Schoder H, Gerecitano J, Hamlin P, Horwitz S, Matasar M, Keskinian VS, McCall S, Noy A, Palomba ML, Portlock C, Straus D, Yahalom J, Younes A, Zelenetz A, Moskowitz CH

Posters**P129**

The prognostic role of different histopathologic growth patterns in nodular lymphocyte-predominant Hodgkin Lymphoma: A report from the German Hodgkin Study Group (GHSG)
Hartmann S, Eichenauer DA, Plütschow A, Mottok A, Bob R, Koch K, Bernd HW, Cogliatti S, Hummel M, Feller AC, Ott G, Möller P, Rosenwald A, Stein H, Hansmann ML, Engert A, Klapper W

P130

A Phase I Study of Bispecific Anti-CD30 x Anti-CD16A Antibody Construct AFM13 in Patients with Relapsed or Refractory Hodgkin Lymphoma
Rothe A, von Tresckow B, Topp MS, Younes A, Eichenauer DA, Hummel H, Reinert KS, Dietlein M, Kessler J, Ravic M, Hucke C, Pogge von Strandmann E, Engert A

P131

Brentuximab vedotin as first line salvage therapy in relapsed / refractory HL
Chen R, Palmer J, Thomas S, Kim Y, Chen BT, Krishnan A, Nathwani N, Sahebi F, Martin P, Mott M, Matsuoka D, Forman S

P132

Phase 1/2 study of brentuximab vedotin in pediatric patients with relapsed or refractory (RR) hodgkin lymphoma (HL) or systemic anaplastic large-cell lymphoma (sALCL): Interim phase 1 safety and pharmacokinetic (PK) data
Locatelli F, Gore L, Mauz-Körholz C, Rosolen A, Landman-Parker J, Sanchez de Toledo J, Beishuizen A, Franklin A, Fasanmade A, Wang J, Fingert H, Labotka R, Neville K

P133

Antitumor activity of brentuximab vedotin in patients with relapsed or refractory (RR) Hodgkin Lymphoma (HL) following autologous stem cell transplant (ASCT): Meta-analysis comparison
Bonthapally V, Wu E, Macalalad A, Yang H, Shonukan O, Liu Y, Chi A, Huebner D

P134

Progression-free survival (PFS) analyses of two pivotal phase 2 studies of brentuximab vedotin in patients with relapsed or refractory (RR) Hodgkin Lymphoma (HL) or systemic anaplastic large-cell lymphoma (sALCL)
Radford J, Younes A, Pro B, Chi A, Westin E, Huebner D, Engert A

P135

A Multicenter, Phase 1/2 Study of JNJ-40346527, a Colony Stimulating Factor-1 Receptor (CSF-1R) Inhibitor, in Patients with Relapsed or Refractory Hodgkin Lymphoma
von Tresckow B, Morschhauser F, Ribrag V, Topp M, Chien C, Seetharam S, Aquino R, Kotoulek S, Khan I, de Boer C, Engert A

P136

Phase II study of ofatumumab plus ESHAP (O-ESHAP) as salvage treatment for patients with relapsed or refractory classical Hodgkin's Lymphoma after first-line chemotherapy

Martínez C, Rodríguez-Calvillo M, García-Sanz R, Terol J, Pérez-Ceballos E, Xicoy B, Cantalapiedra A, Domingo E, Rodríguez-Salazar J, Sampol A, Espeso M, López J, Briones J, Sureda A

P137

A phase III randomized, double blind, placebo controlled multicenter study of panobinostat for maintenance of response in patients with Hodgkin Lymphoma who are at risk for relapse after high dose chemotherapy and autologous stem cell transplant: final results after early trial discontinuation

von Tresckow B, Skotnicki A, Lisukov I, Srivastava S, Morgan D, Morschhauser F, Stelitano C, Szer J, Eichenauer DA, Abramson J, Sureda A, Ferme C, Engert A

P138

Prognostic factors in patients (pts) with relapsed / refractory (R/R) Hodgkin's Lymphoma (HL) treated with IGEV and autologous stem cell transplantation (ASCT): a nationwide retrospective survey from Fondazione Italiana Linfomi (FIL)

Balzarotti A, Anastasia A, Zilioli VR, Spina M, Pulsoni A, Gotti M, Cascavilla N, Angrilli F, Ortu La Barbera E, Botto B, Carella AM, Puccini B, Levis A, Conticello C, Gandolfi S, Tedeschi L, Re A, Massidda S, Giordano L, Brusamolino E, Bellei M, Santoro A

P139

Brentuximab vedotin in relapsed / refractory (RR) Hodgkin Lymphoma (HL) and RR systemic anaplastic large-cell lymphoma (SALCL): a review of international experience in the Named Patient Program (NPP)

Zinzani PL, Sasse S, Radford J, Shonukan O, Bonthapally V

P140

Double transplantation auto / auto or auto / allo in refractory and very unfavorable relapse of Hodgkin Lymphoma (HL) patients: First analysis of early deaths of the prospective multicentric observational study

Deau B, Amorin S, Robin M, Bologna S, Delmer A, Lissandre S, Thepot S, Quittet P, Chaoui D, Gabarre J, Bouabdallah K, Jaubert J, Brice P

P141

Site of relapse after radiotherapy in stage I/II Hodgkin Lymphomas (HL): A monocentric retrospective study of 60 patients

Krebs L, Quero L, Franchi P, Amorin S, Menard J, Hennequin C, Brice P

P142

Significant activity of the mTOR inhibitor sirolimus and HDAC inhibitor vorinostat in heavily pretreated refractory Hodgkin Lymphoma patients

Janku F, Garrido-Laguna I, Velez-Bravo VM, Subbiah V, Hong DS, Falchook GS, Oki Y, Fayad LE, Kwak LW, Shpall EJ, Davis RE, Liang W, Salhia B, Carpten JD, Kurzrock R, Fanale MA

P143

Defining a Hodgkin Lymphoma Population for Novel Therapeutics after Relapse from Autologous Hematopoietic Cell Transplantation

Arai S, Fanale M, deVos S, Engert A, Illidge T, Borchmann P, Younes A, Morschhauser F, McMillan A, Horning SJ

P144

Relapsed / refractory (RR) Hodgkin Lymphoma (HL) following autologous stem cell transplant (ASCT): burden of illness and advancement in treatment

Singh M, Eaton J, Hatton C, Baculea S, Bonthapally V

P145

Nodular lymphocyte predominant Hodgkin's Lymphoma – Evaluation of a scoring system to predict recurrences

Panjwani P, Epari S, Sengar M, Laskar S, Menon H, Shet T

P146

Brentuximab Vedotin and neuropathy, a single center study on 46 patients

Madaoui C, Madelaine I, Deville L, Faure P, Thieblemont C, Brice P

P147

Characteristics and outcome of Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL). A multicentre audit study from the Polish Lymphoma Research Group

Paszkiwicz-Kozik E, Brzeska B, Tajer J, Kotarska M, Zaucha JM, Zaucha R, Kurczab P, Kyrz-Krzemien S, Wrobel T, Kuniega B, Drozd-Sokolowska J, Subocz E, Romejko-Jarosinska J, Kraszewska E, Walewski J

P148

IGEV as salvage regimen therapy for relapsed / refractory Hodgkin Lymphoma

Kacem K, Zriba S, Ghédira H, Mansouri R, Manai Z, Ben Neji H, Zarrouk M, Ben Abdennebi Y, Jeddi R, Aïssaoui L, Belhadj Ali Z, Ben Abid H, M'Sadek F, Ben Lakhal R, Meddeb B

P149

Post-authorisation safety study (PASS) MA25101: an observational cohort study of the safety of Brentuximab Vedotin in the treatment of relapsed or refractory (RR) CD30+ Hodgkin Lymphoma (HL) and RR systemic anaplastic large cell lymphoma (sALCL).

The ARROVEN study

McAuliffe M, Huebner D, Shonukan O, Porter J, Ponsillo M, Exter B, Bowers S, Conlon J, Partyka J, Wang B, Sachs J

P150

Brentuximab Vedotin (SGN-35) in Hodgkin Lymphoma patients with relapsed after autologous peripheral blood stem-cell transplantation

Erdem G, Karadurmus N, Ozaydin S, Karacalioglu AO, Yeginer C, Ozturk M, Ataergin S, Nevruz O, Cetin T, Arpacı F

P151

Allogeneic hematopoietic stem cell transplantation in Hodgkin's Lymphoma – a single center experience

Sucak G, Kurt B, Yeğin ZA, Akı SZ, Özkurt ZN, Acar K

P152

Sequence occurrence of Hodgkin Lymphoma and diffuse large B-cell lymphoma

Jóna A, Irsai G, Barna S, Garai I, Bedekovics J, Magyari F, Gergely L, Illés A

8. Survivorship

Poster presenters are kindly asked to be present at their poster boards during the Posterwalk on Tuesday, October 15th, 13:45 to 14:15 to discuss their research.

Selected for Oral Presentations

T153

Changes in Breast Cancer Risk as Long-Term Hodgkin Lymphoma Survivors Reach Menopausal Age

Wong JS, Catalano PJ, Chen Y, Marcus KJ, Michaelson EM, Mauch PM, Ng AK

T154

Second cancer risk forty years after cure for Hodgkin Lymphoma

Schaapveld M, Aleman BMP, van Eggermond AM, Janus CPM, Krol ADG, van der Maazen RWM, Raemaekers JMM, de Boer JP, Zijlstra JM, van Imhoff GW, Beijert M, Lybeert ML, Poortmans PhMP, Visser O, Louwman M, Lugtenburg PJ, van Leeuwen FE

T155

A Dutch nationwide survivorship care programme for Hodgkin Lymphoma survivors

van Leeuwen FE, Dekker N, van't Veer MB, Lugtenburg P, Krol ADG, van der Maazen RWM, van Imhoff GW, Zijlstra JM, Janus CPM, Ong F, Borger J, Petersen EJ, Poortmans PhMP, Kersten MJ, Vos-Westerman J, Schouten HC, Roesink JM, Beijert M, Meijer OWM, Noordijk EM, de Boer JP, Lybeert M, Schaapveld M, Kremer LC, Aleman BMP, Raemaekers JMM, on behalf of the BETER consortium

Posters**P156**

Systematic review and individual patient data meta-analysis of treatment-related risk of secondary malignant neoplasms after Hodgkin Lymphoma: First results

Eichenauer DA, Franklin J, Kaul I, Engert A

P157

Long-term risk of ischemic heart disease following Hodgkin Lymphoma treatment

van Nimwegen FA, Schaapveld M, Krol ADG, Janus CPM, Cutter D, Darby S, Aleman BMP, van Leeuwen FE

P158

Temporal trends in mortality from diseases of the circulatory system after treatment for Hodgkin Lymphoma – A population-based cohort study in Sweden (1973–2006)

Eloranta S, Lambert PC, Sjöberg J, Andersson TML, Björkholm M, Dickman PW

P159

Risk of valvular heart disease after radiotherapy for Hodgkin's Lymphoma

Cutter DJ, Schaapveld M, van Leeuwen FE, Hauptmann M, Janus C, Krol ADG, van Nimwegen FA, Darby SC, Aleman BMP

P160

Accelerated telomere shortening in peripheral blood lymphocytes of Hodgkin Lymphoma with coronary artery disease

M'Kacher R, Girinsky T, Colicchio B, Ricoul M, Dieterlen A, Jeandidier E, Heidingsfelder L, Cuceu C, Lenain A, Bourhis J, Hempel WM, Carde P, Sabatier L

P161

Prospective Coronary Heart Disease Screening in Asymptomatic Hodgkin Lymphoma Patients Using Coronary CT Angiography (CCTA): Results and Risk Factor Analysis

Girinsky T, M'Kacher R, Lessard N, Koscielny S, Elfassy E, Raoux F, Carde P, Dos Santos M, Marginaud JP, Sabatier L, Ghalibafian M, Paul JF

P162

Roles of radiotherapy, chemotherapy, and hormonal factors in the risk of breast cancer following treatment for Hodgkin's Lymphoma

van Eggermond AM, Schaapveld M, De Bruin ML, Janus CPM, Krol ADG, Aleman BMP, Russell NS, van Leeuwen FE

P163

Risk of Diabetes Mellitus in long-term survivors of Hodgkin Lymphoma

van Nimwegen FA, Schaapveld M, Janus CPM, Krol ADG, van der Maazen RWM, Kremer LCM, Aleman BMP, van Leeuwen FE

P164

Hodgkin Lymphoma in adults: An interdisciplinary evidence-based guideline

Skoetz N, Rancea M, Borchmann P, von Tresckow B, Halbsguth T, Behringer K, Wongso D, Böll B, Klimm B, Thielen I, Eichenauer D, Engert A

P165

Infradiaphragmatic Radiotherapy in Patients with Hodgkin's Lymphoma (HL) –Infertility as a possible consequence –

Baues CM, Müller H, Nast-Kolb B, Celic E, Kriz J, Görgen H, Semrau R, Engert A, Borchmann P, Behringer K

P166

Screening for coronary artery disease after mediastinal irradiation in Hodgkin Lymphoma survivors using computed tomographic angiography: phase II study of indication and acceptance

Daniëls LA, Krol ADG, de Graaf MA, Scholte AJHA, van't Veer MB, Putter H, de Roos A, Schali J, Creutzberg CL

P167

Comparison of rituximab in the first and second line treatment in lymphocyte predominant Hodgkin Lymphoma

Mocikova H, Pytlik R, Stepankova P, Michalka J, Raida L, Markova J, Koren J, Belada D, Kral Z, Kozak T

P168

Survival after high dose therapy with autologous stem cell support for adult relapsed or refractory Hodgkin's Lymphoma in Norway – A national multicenter study

Smeland K, Kiserud CE, Lauritzsen GF, Fosså A, Østenstad B, Kolstad A, Fagerli UM, Fluge Ø, Maisenhølder M, Loge JH, Kvaløy S, Holte H

P169

Prognostic Significance of CD20 Expression and Epstein-Barr Virus (EBV) Association in Classical Hodgkin's Lymphoma

Elsayed AA, Asano N, Ohshima K, Izutsu K, Kinoshita T, Nakamura S

P170

The addition of lymphocyte / monocyte ratio (LMR) to the international prognostic score for Hodgkin Lymphoma identifies low risk patients with adverse prognosis

Tadmor T, Bari A, Marcheselli L, Aviv A, Pozzi S, Liardo EV, Cox MC, Giraffa M, Cascavilla N, Attias D, Ferri P, Sacchi S, Federico M, Polliack A. (The first two authors contributed equally.)

P171

Radiation pulmonary complications in Hodgkin's Lymphoma patients as result of radiotherapy alone or chemo-radiotherapy involving mediastinal irradiation to different total tumor doses

Danilenko A, Shakhtarina S, Afanasova N, Pavlov V

P172

Second neoplasms in young adults following treatment of childhood Hodgkin Lymphoma

Kruseova J, Ganevova M, Cepelova M, Luks A, Krol L, Malis J, Kabickova E, Churackova M, Stary J

P173

The Breast Cancer after Radiotherapy Dataset (BARD): an initiative to improve screening for breast cancer in a high risk cohort of female Hodgkin Lymphoma survivors in England

Radford J, Howell S, O'Hara C, Goode V, Vaughan K, Davies S, Cowan R, Swerdlow A

P174

Clinical and radiological manifestations of pulmonary toxicity in Hodgkin's Lymphoma patients treated with chemotherapy and radiotherapy to total tumor doses 20–30 Gy

Shakhtarina S, Danilenko A, Afanasova N, Pavlov V

P175

Fertility in male patients with Hodgkin Lymphoma treated with BEACOPP regimen

Smardova L, Crha I, Michalka J, Kral Z, Janikova A, Charouzkova J, Mayer J

P176

Combination of fertility preservation strategies in young women with recently diagnosed Hodgkin Lymphoma

Smardova L, Huser M, Michalka J, Zakova J, Kral Z, Crha I, Janikova A, Krizova L, Mayer J, Ventruba P

P177

New prognostic score based on bcl-6 expression and IPS strongly predicts survival in patients with Hodgkin Lymphoma

Antic D, Andelic B, Milic N, Đurašinovic V, Todorovic M, Bila J, Vukovic V, Jelacic J, Mihaljevic B

P178

Acute pulmonary toxicity of bleomycin – incidence and risk factors in a series of Hodgkin Lymphoma (HL) patients treated in a single center

Santos J, Carvalho S, Esteves S, Gomes da Silva M

P179

Testicular function assessment in young men treated for Hodgkin's Lymphoma during childhood and adolescence

Moryl-Bujakowska A, Balwierz W, Malek A, Sztefko K

P180

Proteinuria in Hodgkin's Lymphoma, is it an underestimated finding?

Salihoglu A, Senel TE, Ozbalak M, Elverdi T, Gulturk E, Eskazan AE, Ar MC, Ongoren S, Baslar Z, Aydin Y, Tuzuner N, Soysal T, Ferhanoglu B

P181

The prognostic impact of lymphocyte / monocyte ratio, absolute lymphocyte count and subsets of natural killer cells in peripheral blood in Hodgkin Lymphoma

Mocikova H, Palickova M, Spacek M, Markova J, Kozak T

P182

Late adverse effects of premature menopause in female Hodgkin Lymphoma survivors: design of a cohort study

Krul IM, Opstal-van Winden AWJ, Schagen SB, Zijlstra JM, Appelman Y, Lambalk CB, Lips PTAM, van Dulmen-den Broeder E, Hauptmann M, Krol ADG, Aleman BMP, van Leeuwen FE

P183

Predictive factors of response in Tunisian adult Hodgkin Lymphoma

Kacem K, Zriba S, Ghédira H, Yahyaoui Y, Mansouri R, Dridi M, Hadj Mansour M, Manai Z, Zarrouk M, Ben Neji H, Ben Abdennebi Y, Jeddi R, Aissaoui L, Belhadj Ali Z, Ben Abid H, M'Sadek F, Ben Lakhal R, Meddeb B

P184

Case report of a patient with Hodgkin Lymphoma after treated with TNF alfa inhibitor because of psoriasis and psoriatic arthritis and overview of the literature

Páyer E, Gál A, Szegedi A, Barna S, Illés A

Speakers and Chairs

Abramson, Jeremy S.: jabramson@partners.org
Agarwal, M. B.: mbagarwal@hotmail.com
Aleman, Berthe: b.aleman@nki.nl
Ansell, Stephen: ansell.stephen@mayo.edu
Armitage, James: joarmita@unmc.edu
Behringer, Karolin: karolin.behringer@uk-koeln.de
Bienemann, Kirsten: Kirsten.Bienemann@med.uni-duesseldorf.de
Björkholm, Magnus: magnus.bjorkholm@karolinska.se
Böll, Boris: boris.boell@uk-koeln.de
Borchmann, Peter: peter.borchmann@uni-koeln.de
Carde, Patrice: p.carde@i-o-h.org
Casasnovas, Olivier: olivier.casasnovas@chu-dijon.fr
Cavalli, Franco: franco.cavalli@eoc.ch
Cheson, Bruce: bdc4@georgetown.edu
Coiffier, Bertrand: bertrand.coiffier@univ-lyon1.fr
Connors, Joseph: jconnors@bccancer.bc.ca
Constine, Louis: louis_constine@urmc.rochester.edu
Dabaja, Bouthaina: bdabaja@mdanderson.org
Dann, Eldad J.: e_dann@rambam.health.gov.il
Dekker, Nicky: n.dekker@nki.nl
Diehl, Volker: v.diehl@uni-koeln.de
Diepstra, Arjan: a.diepstra@path.umcg.nl
Dietlein, Markus: markus.dietlein@uk-koeln.de
Dimopoulos, Meletios-Athanassios: mdimop@uoa.gr
Dreyling, Martin: martin.dreyling@med.uni-muenchen.de
Engert, Andreas: a.engert@uni-koeln.de
Evens, Andrew M.: dramevens@mac.com
Federico, Massimo: massimo.federico@unimore.it
Fisher, Richard: richard.fisher@fccc.edu
Fossa, Alexander: AFF@ous-hf.no
Friedberg, Jonathan: jonathan_friedberg@urmc.rochester.edu
Fromm, Jonathan: jfromm@uw.edu
Fuchs, Michael: michael.fuchs@uk-koeln.de
Gallamini, Andrea: gallamini.a@ospedale.cuneo.it
Gascoyne, Randy: rgascoyn@bccancer.bc.ca
Giefing, Maciej: giefingm@man.poznan.pl
Girinsky, Theodore: girinsky@igr.fr

Gisselbrecht, Christian: christian.gisselbrecht@sls.ap-hop-paris.fr
Hagenbeek, Anton: a.hagenbeek@amc.uva.nl
Hallek, Michael: michael.hallek@uni-koeln.de
Hasenclever, Dirk: dirk.hasenclever@imise.uni-leipzig.de
Hemminki, Kari: k.hemminki@dkfz.de
Hodgson, David: david.hodgson@rmp.uhn.on.ca
Hoppe, Bradford: bhoppe@floridaproton.org
Hoppe, Richard: richard.hoppe@stanford.edu
Hummel, Michael: Michael.Hummel@charite.de
Hutchings, Martin: hutchings@dadlnet.dk
Illidge, Tim: tmi@manchester.ac.uk
Janz, Martin: mjanz@mdc-berlin.de
Jarrett, Ruth: Ruth.Jarrett@glasgow.ac.uk
Johnson, Peter: johnsonp@soton.ac.uk
Johnston, Patrick B.: johnston.patrick@mayo.edu
Jones, Kimberly: kimberley.jones@uq.edu.au
Keller, Frank G.: fkeller@emory.edu
Kelly, Kara: kk291@columbia.edu
Kimby, Eva: eva@kimby.se
Klapper, Wolfram: wklapper@path.uni-kiel.de
Klasa, Richard: rklasa@bccancer.bc.ca
Kluge, Regine: Regine.Kluge@medizin.uni-leipzig.de
Körholz, Dieter: dieter.koerholz@uk-halle.de
Kumar, Anita: kumara2@mskcc.org
Küppers, Ralf: ralf.kueppers@uk-essen.de
La Rosee, Paul: Paul.LaRosee@med.uni-jena.de
Landman-Parker, Judith: judith.landman-parker@trs.aphp.fr
Lister, Andrew: a.lister@qmul.ac.uk
Mathas, Stephan: stephan.mathas@charite.de
Metzger, Monika: Monika.Metzger@STJUDE.ORG
Mikhaeel, George: george.mekhaeel@gstt.nhs.uk
Morschhauser, Franck: f-morschhauser@chru-lille.fr
Moskowitz, Craig: moskowic@mskcc.org
Moskowitz, Alison J.: moskowie@mskcc.org
Mounier, Nicolas: mounier.n@chu-nice.fr
Ng, Andrea: ang@lroc.harvard.edu
Peggs, Karl: karl.peggs@cancer.ucl.ac.uk

- Petersen, Peter M.: peter.meidahl.petersen@rh.regionnh.dk
- Preundschuh, Michael: michael.pfreundschuh@uniklinikum-saarland.de
- Pollack, Aaron: apol@cc.huji.ac.il
- Press, Oliver: press@u.washington.edu
- Proctor, Stephen: stephen.proctor@ncl.ac.uk
- Radford, John: John.Radford@manchester.ac.uk
- Raemaekers, John: J.Raemaekers@hemat.umcn.nl
- Rajewsky, Klaus: K.Rajewsky@mdc-berlin.de
- Reichel, Jonathan: mrosnal@gmail.com
- Ricardi, Umberto: umberto.ricardi@unio.it
- Rosenwald, Andreas: rosenwald@uni-wuerzburg.de
- Sattarzadeh, Ahmad: a.sattarzadeh@umcg.nl
- Schaapveld, Michael: m.schaapveld@nki.nl
- Schwartz, Lawrence H.: lhs2120@mail.cumc.columbia.edu
- Shipp, Margaret: Margaret_shipp@dfci.harvard.edu
- Sibon, David: david.sibon@gmail.com
- Specht, Lena: specht@rh.dk
- Stamatoullas, Aspasia: aspasia.stamatoullas@thb.unicancer.fr
- Steidl, Christian: CSteidl@bccancer.bc.ca
- Stein, Harald: h.stein@pathodiagnostik.de
- Sureda, Anna: anna.sureda@addenbrookes.nhs.uk
- Thomsen, Hauke: h.thomsen@dkfz-heidelberg.de
- Van den Berg, Anke: a.van.den.berg@t.umcg.nl
- van Leeuwen, Flora E.: f.v.leeuwen@nki.nl
- von Tresckow, Bastian: bastian.von-tresckow@uk-koeln.de
- Wirth, Thomas: thomas.wirth@uni-ulm.de
- Wong, Julia S.: jwong@trc.harvard.edu
- Xerri, Luc: XerriL@unicancer.fr
- Yahalom, Joachim: yahalomj@mskcc.org
- Younes, Anas: younesa@mskcc.org

FSA-Kodex

We very much like to thank all of our partners for their generous sponsoring.
According to FSA-Kodex (§ 20 Abs. 5) the following companies asked for information about their financial support:

Name of Sponsor		Total Sponsoring Amount	Sponsoring Benefit
Affimed Therapeutics AG, Heidelberg / Germany	Bronze Sponsor	4.500,00 €	Supplement for the congress bag
Amgen GmbH, München / Germany	Silver Sponsor	21.000,00 €	Symposium and Booth
Celgene GmbH, München / Germany	Gold Sponsor	31.400,00.€	Symposium and Booth
Chugai Pharma Marketing, Frankfurt / Germany	Bronze Sponsor	5.000,00 €	Booth
CTI Life Sciences, Heathrow / United Kingdom	Bronze Sponsor	4.000,00 €	Booth
Hexal AG, Holzkirchen / Germany	Bronze Sponsor	4.000,00 €	Booth
Janssen Cilag GmbH, Neuss / Germany	Bronze Sponsor	3.000,00 €	Booth
Janssen Pharmaceutical Research & Development, L.L.C. Raritan, NJ / USA	Silver Sponsor	15.000,00 €	Symposium
MSD Sharp & Dohme GmbH, Haar / Germany	Silver Sponsor	22.400,00 €	Symposium and Booth
PrIME Oncology sponsored by Millennium: The Takeda Oncology Company Cambridge, MA / USA	Platinum Sponsor	64.000,00 €	2 Symposia and Booth
Novartis Pharma GmbH, Nürnberg / Germany	Bronze Sponsor	12.000,00 €	Booth and Educational
Roche Pharma AG, Grenzach-Wyhlen / Germany	Silver Sponsor	20.000,00 €	Symposium and Booth
Sanofi-Aventis Group Paris / France	Bronze Sponsor	4.000,00 €	Educational
Sigma Tau Arzneimittel GmbH, Düsseldorf / Germany	Bronze Sponsor	5500,00 €	Booth and Hodgkin Award
Teva GmbH, Ulm / Germany	Gold Sponsor	33.000,00 €	Symposium and Booth

HODGKIN LYMPHOMA AWARD 2013

The responsibility of saving and securing lives has always been the main vision and motivating factor driving the research of sigma-tau.

The Hodgkin Lymphoma Award is intended to honor medical scientists for outstanding contributions in the field of Hodgkin Lymphoma. The award will be given to:

Anas Younes, M. D.
New York, USA

The following abstracts have been awarded for outstanding contributions:

BEST ABSTRACT AWARD 2013

- Martin Janz (T082)
- Nicolas Mounier (T002)
- Karolin Behringer (T033)
- Patrick B. Johnston (T126)
- Julia S. Wong (T153)

KARL MUSSHOF PRIZE 2013

The Karl Musshoff Foundation was established by Prof. Dr. Karl Musshoff in 1997. The Karl-Musshoff-Prize is granted every three years on the occasion of the ISHL in Cologne for outstanding results in the field of Hodgkin Lymphoma. This years prize for lifetime achievements will be given to:

Prof. Dr. Volker Diehl
Berlin, Germany

YOUNG INVESTIGATOR AWARD 2013

- Jonathan Reichel (T083)
- Dennis A. Eichenauer (P156)
- Anita Kumar (T034)
- Frederika A. van Nimwegen (P157)
- Sandra Eloranta (P158)



Prof. Dr. Andreas Engert (Symposium Chairman)
Dr. Boris Böll (Congress Secretary)
Dr. Bastian von Tresckow (Congress Secretary)
German Hodgkin Study Group
Clinic I for Internal Medicine
University Hospital of Cologne

Hosted by:
Clinic I for Internal Medicine
University Hospital of Cologne
Director: Prof. Dr. Michael Hallek

Design: Atelier Henri Winter

Production: Linsen Druckcenter GmbH

Photos by Courtesy of:
Cologne Tourist Board, Page 15
Intuitivmedia, Page 14
KölnKongress, Pages 16, 17
Carl Victor Dahmen, Pages 14, 15, 27, 33



Gürzenich Congress Center

First Level "Großer Saal"

- | | |
|-----------------|--|
| Sun. 13.10.2013 | Scientific Program
Lunch and Satellite Symposia
Opening Ceremony |
| Mon. 14.10.2013 | Scientific Program
Lunch and Dinner Symposium |
| Tue. 15.10.2013 | Scientific Program
Lunch Symposium
Closing Remarks |

First Level "Isabellensaal"

- | | |
|--------------------------|-------------------------------|
| Sun.-Tue. 13.-15.10.2013 | Exhibition Hall
Coffee Bar |
|--------------------------|-------------------------------|

Ground Floor "Kleiner Saal"

- | | |
|--------------------------|---------------|
| Mon./Tue. 14./15.10.2013 | Posterviewing |
| Tue. 15.10.2013 | Posterwalk |

Foyer Ground Floor

- | | |
|--------------------------|---|
| Sun.-Tue. 13.-15.10.2013 | Registration
Internet
Speakers Ready Room |
|--------------------------|---|

Basement "Weinkeller"

- | | |
|-----------------|--------------|
| Sun. 13.10.2013 | Get Together |
|-----------------|--------------|

Please mark your calendars now for
the 10th International Hodgkin Symposium
which will be held October 2016 in the
Gürzenich, Cologne, Germany.

Further information will be available
on our internet presentation
www.hodgkinsymposium.org .

We look forward to welcoming you
for the 10th Symposium in 2016.

ISHL 10



ISHL-9 Program for your mobile